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Synthetic lethalityIn order to maintain genomic stability, cells have developed sophisticated signalling pathways to enable DNA
damage or DNA replication stress to be resolved. Key mediators of this DNA damage response (DDR) are the
ATM and ATR kinases, which induce cell cycle arrest and facilitate DNA repair via their downstream targets.
Inhibiting the DDR has become an attractive therapeutic concept in cancer therapy, since (i) resistance to
genotoxic therapies has been associatedwith increased DDR signalling, and (ii)many cancers have defects in cer-
tain components of theDDR rendering themhighly dependent on the remaining DDRpathways for survival. ATM
and ATR act as the apical regulators of the response to DNA double strand breaks and replication stress, respec-
tively, with overlapping but non-redundant activities. Highly selective small molecule inhibitors of ATM and ATR
are currently in preclinical and clinical development, respectively. Preclinical data have provided a strong ratio-
nale for clinical testing of these compounds both in combination with radio- or chemotherapy, and in synthetic
lethal approaches to treat tumours with deﬁciencies in certain DDR components. Whole genome sequencing
studies have reported that mutations in DDR genes occur with a high frequency in many common tumour
types, suggesting that a synthetic lethal approachwith ATMor ATR inhibitors could havewidespread utility, pro-
viding that appropriate biomarkers are developed.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).Contents1. Introduction: the DNA damage response— important implications for tumour development and treatment . . . . 124
2. The phosphatidylinositol-3 kinase-related kinase (PIKK) family . . . . . . . . . . . . . . . . . . . . . . 125
3. Ataxia–telangiectasia mutated activation and downstream signalling . . . . . . . . . . . . . . . . . . . . 126
4. Ataxia–telangiectasia and Rad3 related activation and downstream signalling . . . . . . . . . . . . . . . . 127
5. Interplay between the ataxia–telangiectasia mutated and ataxia–telangiectasia and Rad3 related signalling pathways 127
6. Ataxia–telangiectasia mutated as a therapeutic target . . . . . . . . . . . . . . . . . . . . . . . . . . . 127
7. Ataxia–telangiectasia and Rad3 related as a therapeutic target . . . . . . . . . . . . . . . . . . . . . . . 130
8. Synthetic lethal approaches . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 133
9. Biomarkers and patient selection . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 133
10. Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 134
Conﬂict of interest . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 134
Acknowledgments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 134
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 134a–telangiectasia mutated; ATR,
int kinase 1; CHK2, checkpoint
pendent protein kinase catalytic
RRAP; FATC, FAT C-terminal;
1–RAD50–NBS1; PI3K, phos-
-kinase-related kinase; PARP,
ssDNA, single-stranded DNA.
ancer Research UK and Medical
cology, University of Oxford,
44 1865 617409.
. Ryan).
. This is an open access article under1. Introduction: the DNA damage response—
important implications for tumour development and treatment
Cells are invariably challenged by tens of thousands of lesions inﬂicted
on their DNA everyday (Lindhal, 1993). This DNA damage can be caused
exogenously by exposure to different types of radiation or genotoxic
agents, or endogenously through, for example, base depurination and
deamination or reactive by-products of cellular metabolism (Lindahl &
Barnes, 2000). If unrepaired or aberrantly repaired, such lesions maythe CC BY license (http://creativecommons.org/licenses/by/3.0/).
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affect cell viability or induce aberrant cellular behaviour leading to the
development ofmalignancies such as cancer. Because genetic alterations
have such a signiﬁcant potential impact on survival and viability of a cell,
as well as the organism as a whole, cells have developed a complex
network of signalling pathways – collectively known as theDNAdamage
response (DDR) – that orchestrates the detection and repair of DNA
damage with transient cell cycle arrest to ensure maintenance of
genomic stability and cell viability (Jackson & Bartek, 2010; Ciccia
& Elledge, 2011).
The DDR plays an important role in many aspects of cancer. First,
deﬁciencies in DDR mechanisms have been shown to be contributing
factors in many stages of tumour development. Numerous hereditary
cancer predispositions result from mutations in DNA repair genes
(Goode et al., 2002; Negrini et al., 2010). For example, women who
carry a defective allele of the BRCA1 or BRCA2 genes, which encode
for two proteins centrally involved in the repair of DNA double strand
breaks (DSBs) by homologous recombination, are at much higher risk
of developing breast and ovarian cancers than women in the general
population (Pal et al., 2005; Levy-Lahad & Friedman, 2007). Further-
more, several studies have demonstrated activation of DDR proteins
during early stages of tumourigenesis (Bartkova et al., 2005; Gorgoulis
et al., 2005). This response has been linked to the induction of replica-
tion stress and DNA damage, caused by abnormal replication due to
aberrant oncogene activation (Bartkova et al., 2006; Di Micco et al.,
2006). It has been suggested that this activation of DDR pathways may
limit tumour development in its early stages by acting as a barrier for
proliferation of aberrant cells (Bartkova et al., 2005; Gorgoulis et al.,
2005), particularly through activation of the tumour suppressor protein
p53 (Halazonetis et al., 2008). Therefore, it is unsurprising that many
malignant tumours show functional loss or deregulation of key proteins
involved in the DDR and cell cycle regulation, most notably p53 and
ATM (Cancer Genome Atlas Research Network, 2012a, 2012b, 2012c,
2014; Kandoth et al., 2013), MRE11 (Ottini et al., 2004; Bartkova et al.,
2008; Choudhury et al., 2010), BRCA1/2 (Cancer Genome Atlas
Research Network, 2012c; Kandoth et al., 2013) or SMC1 (Kandoth
et al., 2013). Such mutations may allow pre-cancerous cells to breach
the proliferation barrier posed by the DDR, thereby allowing the
progression of pre-malignant lesions to malignant carcinomas. In addi-
tion, deregulation of DDRpathways also contributes to thedevelopment
of genomic instability, a characteristic of human cancers that accelerates
the genetic alterations which drive tumour development (Negrini et al.,
2010; Hanahan & Weinberg, 2011).
DDR mechanisms are also relevant to the effectiveness of standard
cancer treatments, such as radio- and chemotherapy. These treatments
rely on the induction of DNA damage, which is particularly cytotoxic for
proliferating cells and hence, very effective in targeting highly prolifer-
ative cancer cells. Cancer cells can, however, resist the lethal effects of
genotoxic cancer therapy by activating the DDR (Karnitz et al., 2005;
Myers et al., 2009;Woods & Turchi, 2013), and since chemo- and radio-
therapy generally lack selectivity towards cancer cells, the toxicity
induced in normal tissues and the resulting side effects are limiting
factors for the dose and duration of therapy. This is one of the reasons
why these therapies, though effective, often fail to be curative. Also,
tumours can develop resistance to radio- or chemotherapy allowing
tumour recurrence following an initial response to therapy. Several
studies have shown, that the development of resistance to different
types of genotoxic therapy can be caused by deregulation and over-
expression of different components of the DNA damage response
(Bao et al., 2006; Oliver et al., 2010; Bobola et al., 2012).
Regulators of the DDR have therefore become attractive targets for
cancer therapy primarily through two potential approaches. First, to
be used as chemo- or radiosensitisers to increase the effectiveness of
standard genotoxic treatments and to help prevent or overcome the
development of resistance. Second, to exploit defects in DDR mecha-
nisms as potentially targetable weaknesses through synthetic lethalapproaches. While defects in DDR components may, on the one hand,
give cancer cells a growth advantage, allowing them to survive and
proliferate despite oncogene-induced replication stress and genomic
instability, theymay also drive a reliance of cancer cells on any remaining
DDR pathways in order to survive DNA damage. Targeting of such
remaining pathways may therefore be selectively toxic to cancer cells
with mutations in certain DDR genes. The potential of this approach
was ﬁrst demonstrated in cells harbouring mutations in the breast
and ovarian cancer susceptibility genes BRCA1 and BRCA2, which
were shown to be highly sensitive to small molecule inhibitors of
poly(ADP-ribose)-polymerase (PARP), a DDR protein that is involved
in the detection and repair of DNA single strand breaks by base excision
repair (Bryant et al., 2005; Farmer et al., 2005). The PARP inhibitor
olaparib has since shown promise for the treatment of BRCA1/2mutated
breast or ovarian cancer in clinical trials (Fong et al., 2009; Audeh et al.,
2010; Tutt et al., 2010). Further studies havedemonstrated that inhibition
of other components of the DDR machinery can sensitise cancer cells to
DNA damaging treatments, including DNA-PKcs (Zhao et al., 2006),
ataxia–telangiectasia mutated (ATM) (Rainey et al., 2008; Golding
et al., 2012), ataxia–telangiectasia and Rad3 related (ATR) (Fokas et al.,
2012; Pires et al., 2012; Prevo et al., 2012; Huntoon et al., 2013), or their
downstream targets CHK1 and CHK2 (Matthews et al., 2007; Blasina
et al., 2008; Mitchell et al., 2010; Riesterer et al., 2011).
Here, we focus on the role of ATR and ATM in the DNA damage
response and the current status of development of speciﬁc inhibitors
targeting these pathways.We review the studies elucidating the potential
of these inhibitors to act as radio- and chemosensitisers and discuss the
genetic alterations or cellular phenotypes that suggest which patient
subsets may beneﬁt most from these therapies. We also give examples
of synthetic lethal approaches that target these two DDR kinases.
2. The phosphatidylinositol-3 kinase-related kinase (PIKK) family
ATM and ATR are members of the phosphatidylinositol 3-kinase-
related kinase (PIKK) family of serine/threonine protein kinases, which
also comprises DNA-dependent protein kinase catalytic subunit
(DNA-PKcs/PRKDC), mammalian target of rapamycin (MTOR/FRAP)
and suppressor of morphogenesis in genitalia (SMG1). The cellular
functions of these protein kinases range from regulation of the DNA
damage response (DDR) to cell survival, proliferation, metabolism, differ-
entiation, motility and nonsense-mediated mRNA decay (Lempiäinen &
Halazonetis, 2009; Jackson & Bartek, 2010; Ciccia & Elledge, 2011). A
sixthmember of the PIKK family, transformation/transcription associated
protein (TRRAP), serves as component of various histone acetyltransfer-
ase complexes and plays a role in the epigenetic regulation of transcrip-
tion, but possesses no kinase activity (Lempiäinen & Halazonetis, 2009).
Themembers of the PIKK kinase family show considerable similarities
in their domain architecture and extensive sequence homology,
particularly in their C-terminal kinase domain and the ﬂanking FAT
(FRAP–ATM–TRRAP) and FATC (FAT C-terminal) domains (Fig. 1)
(Keith & Schreiber, 1995; Bosotti et al., 2000). Even though the functions
of the FAT and FATC domains are not yet fully understood, both domains
have been implicated in the regulation of kinase activity. The N-terminal
region is poorly conserved between PIKK family members and is
believed to be important for the interaction with various substrates
and adapter proteins (Fernandes et al., 2005).
In ATR, the N-terminus also contains the binding site for ATRIP
(ATR-interacting protein), which regulates the localisation of ATR
to sites of replication stress and DNA damage and is essential for ATR
signalling (Cortez et al., 2001; Zou & Elledge, 2003).
Many reports have linked members of this kinase family to
tumourigenesis and survival of cancer cells following therapy, rendering
these kinases attractive potential targets for cancer treatment. However,
the development of selective inhibitors has not been without difﬁculty,
due to the high degree of homology in the kinase domain, increasing
the likelihood of inhibition of other PIKK family members, which may
Fig. 1. Schematic diagrams of the domain structure of phosphatidylinositol 3-kinase-related kinases (PIKKs). Known structural domains are shown for each protein. ATM (ataxia–telangiectasia
mutated), ATR (ataxia–telangiectasia and Rad3 related), PRKDC (DNA-dependent protein kinase catalytic subunit; DNA-PKcs), SMG1 (suppressor of morphogenesis in genitalia), MTOR
(mammalian target of rapamycin), FAT (FRAP–ATM–TRRAP domain), FATC (FAT C-terminal domain), PIKK (phosphatidylinositol 3-kinase-related kinase domain), TAN (Tel1/ATMN-terminal
motif), ATRIP (ATR interacting protein), UME (UVSB PI3 kinase,MEI-41 and ESR1domain), NUC194 (domain B in the catalytic subunit of DNA-dependent protein kinase), RBD (rapamycin
binding domain), HEAT (Huntingtin, elongation factor 3, protein phosphatase 2A, and the yeast kinase TOR1-like repeat).
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cross-reactivity, which will be discussed later.
3. Ataxia–telangiectasia mutated
activation and downstream signalling
Of the many different types of DNA lesions, DNA double strand
breaks (DSBs) are amongst the most deleterious. It has been suggested
that a single unrepaired DSB may be sufﬁcient to induce cell death
(Bennett et al., 1993), whereas misrepaired DSBs can result in loss of
genetic information, potentially harmful mutations or chromosomal
rearrangements, which can lead to cancer development.
ATM is one of the central kinases involved in the cellular response
to DNA DSBs which may arise, for example, intrinsically through the
collapse of stalled replication forks or extrinsically through exposure
to ionising radiation (IR) (van Gent et al., 2001). Despite great
advancement in our understanding of ATM signalling and function
in recent years, the complex mechanisms involved in its activation
are not yet fully resolved.
In its inactive state, ATM forms homodimers or higher order
multimers which dissociate into active monomers following rapid
intermolecular autophosphorylation of serine 1981 uponATMactivation
(Bakkenist & Kastan, 2003). Since the initial discovery of this auto-
phosphorylation site and its role in ATM activation, other ATM post-
translational modiﬁcations have been reported, including additional
phosphorylation sites and an acetylation site, which regulate ATM
activity (Kozlov et al., 2006; Sun et al., 2007). The recruitment of
ATM to sites of DNA DSBs is mediated via the MRE11–RAD50–NBS1
(MRN) complex (Lee & Paull, 2005). The MRN complex quickly
assembles at sites of DNA DSBs, where it acts as a damage sensor
that can also form a physical bridge spanning the DSB (Stracker &
Petrini, 2011). ATM recruitment has been shown to require its bindingto the C-terminus of NBS1, an interaction that also enhances the kinase
activity of ATM (You et al., 2005). Immediately following its recruitment
to sites of DNA DSBs, ATM contributes to the phosphorylation of the
histone variant H2AX on Serine 139 (referred to as γH2AX) (Burma
et al., 2001). H2AX phosphorylation in turn initiates a cascade
which assembles DDR components at the breakage site (Paull et al.,
2000; Scully & Xie, 2013). Interestingly, MRN complex components
not only modulate the activity of ATM, but are also amongst its
downstream targets (Lim et al., 2000; Di Virgilio et al., 2009; Gatei
et al., 2011, 2000). This suggests that ATM and the MRN complex
work together at the sites of DNA DSBs to ﬁne-tune the recruitment
and dissociation of DDR factors and promote effective DNA damage
repair.
ATM plays a crucial role in the activation of the G1/S cell cycle
checkpoint, which prevents cells with damaged DNA from entering
S-phase. This response is primarily mediated through the tumour
suppressor protein p53, which was one of the ﬁrst ATM downstream
targets to be reported. In response to the induction of DNADSBs, ATMdi-
rectly phosphorylates p53 on serine 15 (Kastan et al., 1992; Siliciano
et al., 1997; Banin et al., 1998; Canman et al., 1998). Checkpoint kinase
2 (CHK2) a key downstream target of ATM (Matsuoka et al., 1998) and
mediator of ATM signalling also phosphorylates p53, on serine 20
(Chehab et al., 1999, 2000). This phosphorylation of p53 leads to its
stabilisation by preventing its Mdm2-mediated ubiquitinylation and
degradation (Haupt et al., 1997; Chehab et al., 1999; Marine & Lozano,
2010). ATM further contributes to the accumulation and stabilisation of
p53 by directly phosphorylating Mdm2 (Khosravi et al., 1999). Upon
activation and accumulation in the nucleus, p53 acts as transcription
factor and drives the expression of genes involved in cell cycle checkpoint
activation, such as p21, but also several genes which are involved in the
induction of apoptosis (Sullivan et al., 2012). In addition to its role in
the G1/S checkpoint, ATM also contributes to the activation of an
127A.M. Weber, A.J. Ryan / Pharmacology & Therapeutics 149 (2015) 124–138intra-S-phase checkpoint, as cells deﬁcient in ATM do not reduce DNA
synthesis following induction of DNA DSBs, a phenotype referred to as
radioresistant DNA synthesis (Houldsworth & Lavin, 1980; Falck et al.,
2001). The S-phase checkpoint functions of ATM in response to IR are
partly mediated through phosphorylation of NBS1 and SMC1, a compo-
nent of the cohesion complex (Lim et al., 2000; Kitagawa et al., 2004).
Additional enforcement of the intra-S-phase checkpoint by ATM is
mediated through its activation of CHK2, which induces ubiquitinylation
and degradation of the S-phase-promoting phosphatase Cdc25A
(Falck et al., 2001). Cdc25A promotes S-phase progression through
activation of the cyclin-dependent kinase 2 (Cdk2) that is needed
for DNA synthesis.
Recent studies have demonstrated that in response to IR, hundreds
of substrates are phosphorylated in an ATM-dependent manner, clearly
demonstrating the complexity of the ATM-mediated DDR pathways
(Matsuoka et al., 2007; Bennetzen et al., 2010; Bensimon et al., 2010).
However, evidence suggesting that DDR-independent roles of ATM is
also emerging. It has been shown that ATM functions in the regulation
of signalling pathways involved in maintaining cellular homeostasis,
including cellular metabolism, responses to hypoxia and oxidative
stress (Ditch & Paull, 2012).
4. Ataxia–telangiectasia and Rad3
related activation and downstream signalling
Like ATM, ATR is one of the central kinases involved in the DDR. ATR
is activated by single stranded DNA structures, which may for example
arise at resected DNA DSBs or stalled replication forks. When DNA poly-
merases stall during DNA replication, the replicative helicases continue
tounwind theDNAaheadof the replication fork, leading to the generation
of long stretches of single stranded DNA (ssDNA), which are then bound
by the single-strand binding protein complex RPA (Replication protein
A) (Wold, 1997; Byun et al., 2005). The recruitment of ATR/ATRIP
complexes to these sites of replication stress and DNA damage is
mediated by direct interaction of ATRIP with ssDNA-bound RPA
(Zou & Elledge, 2003). Furthermore, RPA–ssDNA complexes stimulate
the binding of the RAD17/RFC2-5 clamp loader complex to the damage
sites. The presence of a dsDNA–ssDNA junction activates this complex
to load the RAD9–HUS1–RAD1 (9–1–1) heterotrimer onto the DNA
ends (Ellison & Stillman, 2001). The 9–1–1 complex in turn recruits
TopBP1 which activates ATR (Kumagai et al., 2006; Delacroix et al.,
2007; Lee et al., 2007).
Once activated, ATR acts via its downstream targets to promote DNA
repair, stabilisation and restart of stalled replication forks and transient
cell cycle arrest (Chen, 2000; Tibbetts et al., 2000; Sørensen et al., 2003;
Xiao et al., 2003; Cimprich & Cortez, 2008; Dai & Grant, 2010; Errico &
Costanzo, 2012). Many of these functions are mediated through the
ATR downstream target CHK1. ATR plays an important role in the
enforcement of the Intra-S-phase cell cycle checkpoint during normal
S-phase progression and in response to DNA damage. It inhibits the
ﬁring of replication origins via mediating the degradation of Cdc25A
through CHK1, which in turn slows the progression of DNA replication
and provides time for resolution of the stress source (Sørensen et al.,
2003; Xiao et al., 2003; Bartek et al., 2004). ATR is also a principal
mediator of the G2/M cell cycle checkpoint to prevent the premature
entry of cells into mitosis, before DNA replication is completed or in
the presence of DNA damage. This ATR dependent G2/M cell cycle ar-
rest is primarily mediated through two mechanisms: (i) the degra-
dation of Cdc25A (Zhao et al., 2002; Xiao et al., 2003) and (ii) the
phosphorylation of the Cdc25C phosphatase on serine 216 by
CHK1, which creates a binding site for 14-3-3 proteins (Peng et al.,
1997; Sanchez et al., 1997). The binding of Cdc25C to 14-3-3 proteins
facilitates its export from the nucleus and cytoplasmic sequestration,
thereby inhibiting its ability to dephosphorylate and activate nuclear
Cdc2, which in turn prevents entry into mitosis (Kumagai & Dunphy,
1999; Graves et al., 2001).5. Interplay between the ataxia–telangiectasia mutated
and ataxia–telangiectasia and Rad3 related signalling pathways
Although ATM and ATR are activated by different types of DNA
damage and act in distinct pathways, their downstream targets and
the mediated responses are partially overlapping and dependent
on the type of genotoxic stress (Helt et al., 2005). Both kinases
share substrate speciﬁcity, that is they preferentially phosphorylate
serine or threonine residues followed by glutamine (SQ/TQ motif)
(Kim et al., 1999; O'Neill et al., 2000; Matsuoka et al., 2007). A
large-scale proteomic study analysing proteins phosphorylated on
consensus sites recognized by ATM and ATR in response to DNA
damage identiﬁed over 700 putative targets (Matsuoka et al., 2007).
Several of those targets, like p53 and the histone variant H2AX have
been shown to be common targets of both kinases (Banin et al., 1998;
Canman et al., 1998; Tibbetts et al., 1999; Burma et al., 2001; Ward &
Chen, 2001; Friesner et al., 2005). Even CHK1, which is often considered
to be themost speciﬁc ATRdownstream target, canbe phosphorylated by
ATM in response to IR on both Ser317 and Ser345 (Gatei et al., 2003;
Sørensen et al., 2003; Helt et al., 2005). Through these common down-
stream targets, ATM and ATR cooperate in mediating the cellular
responses to many genotoxic stresses and are together responsible
for the maintenance of genomic stability by coordinating cell cycle
progression with DNA repair (Abraham, 2001; Shiloh, 2003; Cimprich
& Cortez, 2008).
ATM is generally regarded to be the principalmediator of the G1 cell
cycle checkpoint, whereas the induction of the intra-S-phase and G2/M
checkpoints are usually primarily related to ATR function. However,
several studies havedemonstrated that, dependingon the cellular context
and type of DNA damage, ATM also contributes to the activation and
maintenance of the intra-S-phase and G2/M cell cycle arrest, suggesting
a functional overlap of ATM and ATR signalling in checkpoint activation
(Abraham, 2001; Shiloh, 2001). One example is the abovementioned
enforcement of the intra-S-phase checkpoint, where both ATM and ATR
can target the Cdc25A phosphatase for ubiquitin-dependent degradation
thereby regulating the timing of replication origin ﬁring in response to
DNA damage (Falck et al., 2001; Xiao et al., 2003; Bartek et al., 2004).
This suggests that both ATM and ATR are required for effective activation
of the intra-S-phase checkpoint following DNA damage (see Fig. 2). ATM
has also been demonstrated to mediate phosphorylation of Cdc25C via
CHK2, thereby contributing to the activation of the G2/M cell cycle
checkpoint (Matsuoka et al., 1998; Shiloh, 2001; Shiloh, 2003). In
agreement with this, Thanasoula et al. have recently demonstrated that
both ATM and ATR play a role in preventing telomere dysfunction-
driven genomic instability through blockingmitotic entry with uncapped
telomeres via degradation of the Cdc25C phosphatase (Thanasoula et al.,
2012). Furthermore, studies in Drosophila and ﬁssion yeast have
implicated that ATM and ATR control partially redundant pathways
for telomere maintenance (Bi et al., 2005; Subramanian & Nakamura,
2010). A functional interplay betweenATMandATR in themaintenance
of fragile site stability has also been suggested (Ozeri-Galai et al., 2008).
In conclusion, even though the ATM and ATR signalling pathways
are not overall redundant, they are partially overlapping. Defects in
one pathway may therefore, at least in part, be compensated for by
the respective other pathway.
6. Ataxia–telangiectasia mutated as a therapeutic target
ATM is a known tumour suppressorwhich is frequentlymutated in a
broad range of human cancers including lung (Cancer Genome Atlas
Research Network, 2012b, 2014), colorectal (Cancer Genome Atlas
Research Network, 2012a), breast (Cancer Genome Atlas Research
Network, 2012c) and haematopoietic cancers (Beà et al., 2013; Landau
& Wu, 2013).
The initial scientiﬁc interest in ATMwas, however, not focused on its
role in tumour development. ATM was ﬁrst described in 1995 as the
Fig. 2.OverviewofATM- andATR-dependentDNAdamage induced cell cycle checkpoint signalling. TheATMandATR kinases are activated by thepresenceofDNAdouble strand breaks or
DNA replication stress, respectively. Cell cycle progression is halted primarily through ATM and ATR dependent phosphorylation of p53, CHK1 and CHK2. G1/S cell cycle arrest is primarily
mediated through a p53-dependent increase in p21, a cyclin-dependent kinase inhibitor. Key targets of CHK1/2 include the Cdc25 phosphatases that control the activity of speciﬁc cyclin–CDK
complexes, which in turn regulate progression through S-phase and entry into mitosis. Phosphorylation of Cdc25 phosphatases by CHK1 or CHK2 inhibits their activity ensuring
that CDK–cyclin complexes are not activated. This leads to cell cycle arrest either in S-phase or at the G2/M boundary. There are overlaps between ATM- and ATR-dependent
checkpoint signalling. Notably, both CHK1 and CHK2 can phosphorylate Cdc25A and Cdc25C, depending on the source of genotoxic stress and there is direct crosstalk between
ATM and ATR following their activation.
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ataxia–telangiectasia (A–T) (Savitsky et al., 1995). This disease, caused
by a loss of ATM function, is characterized by progressive cerebellar
degeneration, telangiectasia, immunodeﬁciency, genomic instability,cancer susceptibility and profound sensitivity to ionising radiation (IR)
(Taylor et al., 1975; Lavin, 2008). It is primarily this hypersensitivity of
ATM-defective cells to IR that has sparked considerable interest in ATM
as therapeutic target for cancer therapy (see Table 1).
Table 1
ATM inhibitors.
Compound Targets Description References
Caffeine ATM/ATR Caffeine sensitises cells to genotoxic modalities, particularly IR.
Caffeine shows an increased radiosensitising effect in cells with p53-deﬁciency.
Powell et al., 1995; Yao et al., 1996;
Bracey et al., 1997; Blasina et al., 1999;
Sarkaria et al., 1999
Wortmannin ATM, PI3K,
DNA-PKcs
Radiosensitises cells in vitro through inhibition of both ATM and DNA-PKc
Highly toxic in vivo
Price and Youmell, 1996; Sarkaria et al.,
1998; Karve et al., 2012
CP-466722 ATM Highly selective ATM inhibitor which radiosensitises cells in vitro
First report that transient inhibition of ATM is sufﬁcient to confer radiosensitivity.
Rainey et al., 2008
KU-55933 ATM First potent and selective ATM inhibitor
Confers marked sensitisation to IR and DNA DSB inducing chemotherapeutics
Not suitable for in vivo use due to high lipophilicity
Hickson et al., 2004
KU-60019 ATM Analogue of KU-55933 with improved potency and solubility in aqueous solutions.
Potently inhibits ATM downstream signalling and sensitises cells to IR in vitro
Radiosensitised glioblastoma cells to IR in vivo following injection of the compound
directly into the tumour. Possesses poor bioavailability in vivo otherwise
Golding et al., 2012, 2009
Biddlestone-Thorpe et al., 2013
KU-559403 ATM First potent and selective ATM inhibitor with good enough solubility and bioavailability
to allow for in vivo studies
Confers radiosensitivity in vitro
Greatly increased the anti-tumour activity of etoposide and irinotecan in xenograft
models
Batey et al., 2013
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which inhibits the function of both ATM and ATR, sensitises cancer cells
to the lethal effects of genotoxic modalities, particularly IR (Blasina
et al., 1999; Sarkaria et al., 1999). Interestingly, this sensitising effect
was more pronounced in cells defective in p53, indicating that ATM
and/or ATR inhibition might be particularly effective for the treat-
ment of p53-deﬁcient tumours (Powell et al., 1995; Yao et al., 1996;
Bracey et al., 1997). Despite the value of caffeine as an experimental
tool for in vitro studies, it is not a clinically useful radiosensitising agent
due to systemic toxicity at the doses required for radiosensitisation and
the low serum levels that can be achieved in patients (Newton et al.,
1981).
Wortmannin, a drug originally described as inhibitor of PI3K family
members, has also been described as a potent radiosensitiser (Price &
Youmell, 1996), an effect subsequently shown to be mediated through
potent inhibition of both ATMandDNA-PKcs (Sarkaria et al., 1998). How-
ever, similar to caffeine, a lack of selectivity and high in vivo toxicity has
hindered further development of this drug for the clinic (Karve et al.,
2012).
In 2008, Rainey et al. published the results of a targeted compound li-
brary screen for potential inhibitors of the ATM kinase. In this study, the
compound CP466722 was identiﬁed as a highly selective and rapidly re-
versible ATM inhibitor, which did not inhibit PI3K or related PIKK family
members. Most importantly, the authors were able to not only validate
the radiosensitising effect mediated by ATM inhibition, but also showed
that transient inhibition of ATM is sufﬁcient to achieve a signiﬁcant in-
crease in radiation-induced cytotoxicity (Rainey et al., 2008). This raises
the possibility that clinically relevant radiosensitisation may not requireprolonged ATM inhibition which could help to reduce side effects in a
clinical setting.
Starting out from the chemical structure of the PI3K inhibitor
LY294002, KuDOS Pharmaceuticals (in 2005 acquired by AstraZeneca)
developed the ﬁrst potent and selective ATM inhibitor: KU-55933. In a
study published in 2004, Hickson et al. demonstrated, that KU-
55933 confers marked sensitisation to ionising radiation and DNA
DSB-inducing chemotherapeutics, such as the topoisomerase II
inhibitors etoposide and doxorubicin, in cancer cells. Importantly, in
cells derived from A–T patients, which express no functional ATM, no
radiosensitisation was observed, further conﬁrming the selectivity of
the compound for ATM (Hickson et al., 2004).
To improve the pharmacokinetics and bio-availability, the core
structure of KU-55933 was further optimised which led to the develop-
ment of KU-60019, which, like KU-55933, is an ATP-competitive ATM
inhibitor. It was shown to be more effective at blocking radiation-
induced phosphorylation of ATM downstream targets than KU-55933
and to possess greater potency as radiosensitiser (Golding et al., 2009).
Again, A–T ﬁbroblasts were not radiosensitised by the compound,
arguing for ATM being speciﬁcally targeted. This and further in vitro
studies demonstrated potent radiosensitisation of several glioblastoma
cell lines byKU-60019 – a promising observation given that glioblastoma
cells are usually very resistant to radiotherapy. Notably, viability of
cultured human astrocytes, which are terminally differentiated and
not actively dividing, was not affected by short-term exposure to
KU-60019. This observation suggests that ATM inhibition alone is not
toxic for normal brain tissues outside the radiation ﬁeld (Golding et al.,
2012). Even though KU-60019 showed better solubility in aqueous
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tered intraperitoneally or orally, systemic plasma levels only reach low
micromolar concentrations (Biddlestone-Thorpe et al., 2013), limiting
utility for in vivo studies. Biddlestone-Thorpe et al. bypassed this
limitation by directly injecting KU-60019 into orthotopic gliomas
grown in mice. They showed that ATM inhibition by KU-60019
markedly radiosensitised the glioma xenografts in vivo, leading to a
signiﬁcant increase in survival time of the mice. Importantly, KU-60019
showed an even greater radiosensitising effect in p53-mutant glioma,
resulting in extended survival and, in some cases, apparent cure of the
treated mice (Biddlestone-Thorpe et al., 2013). Though KU-60019
may not be of clinical utility, this proof-of-principle study provided
evidence that pharmacological ATM inhibition can induce a potent
radiosensitisation of cancer cells in vivo.
Recently, KU-59403, another ATM inhibitor from this class of
compounds, has been described. This compound not only possesses
improved potency over KU-55933, it also exhibits improved solubility
and bio-availability, allowing for the study of effects of pharmacological
ATM inhibition in animal models of human cancer. Batey et al. demon-
strated that following administration to mice, KU-59403 showed good
tissue distribution. In subcutaneous tumour xenografts, concentrations
above those required for in vitro activity were reached and maintained
for at least 4 h (Batey et al., 2013), making this the ﬁrst reported in vivo
active ATM inhibitor. In this study, it was shown that while KU-59403
alone had no impact on tumour growth rate, it greatly enhanced the
anti-tumour activity of the topoisomerase inhibitors etoposide and
irinotecan. Notably, the authors found the presence of KU-59403
at the time of etoposide dosing necessary to observe the chemo-
sensitising effect. In contrast, delaying administration of KU-59403
by only 4 h completely abolished chemosensitisation. Contrary to
Biddlestone-Thorpe et al., Batey and colleagues found that chemo-
and radiosensitisation by ATM inhibition was not p53-dependent.
Possible causes for this discrepancy include the use of different in-
hibitors and administration routes or the use of different tumour
models (orthotopic glioma vs. subcutaneous colon cancer models).
A contributing factor could also be the nature of the p53 mutations
that the cancer cells carry as loss of function, dominant negative or
gain of function mutations in p53 may affect therapeutic responses
of cancer cells in different ways. Also, the increased sensitivity of
p53-deﬁcient glioma cells to ATM inhibition in combination with
ionising radiation observed by Biddlestone-Thorpe was only seen
in vivo and not in vitro. The radiosensitising effect of KU-59403,
however, was only studied in vitro. Further studies will be required
to address the question if the functional status of p53 plays a role
in the radiosensitising potency of ATM inhibitors.
Despite the fact that no ATM inhibitors are in clinical development
yet, the in vitro studies carried out to date clearly show that pharmaco-
logical ATM inhibition has great potential as a cancer therapy in
combination with radiotherapy or certain chemotherapeutic drugs
(like topoisomerase inhibitors). The continuous improvement and
optimisation of chemical structures and screening of compound
libraries have led to the development of increasingly potent and speciﬁc
inhibitors that show improving properties for in vivo use. These develop-
ments are clearly encouraging for further development of ATM inhibitors
for the clinic.
There are however, concerns of potential side-effects that should
also be taken into account. Even though some studies pointed towards
a potentially greater radiosensitising effect in p53-deﬁcient tumours,
ATM inhibition radiosensitises cells in general, which raises the concern
of normal tissue toxicity. It should also be noted that pharmacological
ATM inhibition appears to cause a different cellular phenotype than
lack of ATM protein expression. Choi et al. showed that following
exposure to IR, repair of damaged DNA replication forks is normal in
A–T cells, which lack ATM protein, but is defective in wild-type cells
when ATM is inhibited by KU-55933 or KU-60019. This effect of ATM
inhibitor treatment was not observed in A–T cells (White et al., 2010).The authors hypothesised that “kinase-inhibited ATM” presents a
physical impediment to sister chromatid exchange, a mechanism of
homologous recombination repair (HRR), at DSBs at damaged replication
forks (Choi et al., 2010; White et al., 2010).
Interestingly, it has been shown recently that the expression of
kinase dead (kd) ATM protein is more detrimental to cells than loss of
ATM expression (Yamamoto et al., 2012). While ATM knockout mice
have long been known to be viable, yet recapitulating many of the
symptoms characteristic for A–T (Barlow et al., 1996; Elson et al.,
1996), expression of physiological levels of kd ATM led to early
embryonic lethality in mice. It has been suggested that this is due
to the binding of catalytically inactive ATM to sites of DNA DSBs,
thereby blocking those sites for proteins mediating alternative
routes of DNA damage repair, and causing disturbance of the DDR
and persistence of DNA damage (Yamamoto et al., 2012). ATP-
competitive ATM inhibitors like KU-55933 might act in a similar way
as kd ATMprotein, which, upon prolonged exposure, may cause greater
side effects in vivo than a loss of ATMprotein expressionwould. Further
studies will need to address this question, but the possibility should be
considered for future clinical development of ATM inhibitors.
However, given the observations that (i) transient inhibition of ATM
is sufﬁcient to achieve radiosensitisation in vitro (Rainey et al., 2008)
and (ii) ATM must be inhibited at the time of etoposide administration
(Batey et al., 2013) to achieve chemosensitisation in vivo, there is strong
indication that short-term treatment with optimally-scheduled ATM
inhibitors might be sufﬁcient to achieve chemo- or radiosensitisation.
In addition to the clinical use of ATM inhibitors as radiosensitisers,
ATM deﬁciency in tumours might be exploitable as an “intrinsic
radiosensitiser”. As mentioned earlier, ATM is frequently mutated in a
variety of cancer types (Cancer Genome Atlas Research Network,
2012a, 2012b, 2012c, 2014). However, the large size of the ATM gene
renders routine DNA sequencing a challenging diagnostic tool and a
large proportion of the ATM mutations reported to date are missense
variants, which occur across the entire length of the ATM protein,
with no apparent hotspots. Predicting the consequences of such
mutations on protein stability and activity is challenging without
functional studies. Studies on ATM missense mutations found in
ataxia–telangiectasia (A–T) patients have shown, however, that
missense changes can lead to a reduction in ATM protein expression
and that loss of ATM activity is often associated with reduced ATM
protein levels (Sandoval et al., 1999; Lavin et al., 2004; Mitui et al.,
2009; Jacquemin et al., 2012). In our own studieswe have demonstrated
that cancer-associated ATMmutations can lead to a reduction or loss of
ATM protein expression and consequently impairment of the ATM
signalling pathway. Furthermore we were able to show that analysis of
ATM protein expression by immunohistochemistry may be a valuable
clinical tool to identify a patient subgroup with low or absent ATM
protein levels (Weber et al., 2014). Furthermore, studies in locally
advanced breast cancer have demonstrated that the ATM gene is a
potential target for epigenetic silencing (Vo et al., 2004). Hypermethyla-
tion of the ATM promoter resulting in decreased protein levels and
increased radiosensitivity has been described for colorectal and glioma
cell lines (Kim et al., 2002; Roy et al., 2006). A report by Tribius et al.
suggested a correlation between ATM protein levels and radiosensitivity
in primary glioblastoma cells in culture (Tribius et al., 2001).
Identifying loss of ATM function in tumour cells might therefore
allow for the identiﬁcation of a patient subset that could receive
increased beneﬁt from radiation therapy. However, this possibility will
have to be addressed in future studies.
7. Ataxia–telangiectasia and Rad3 related as a therapeutic target
Several concerns revolving around functional inhibition of ATR have
hindered the exploitation of ATR as therapeutic target in cancer therapy
and delayed the development of speciﬁc ATR kinase inhibitors. It
was anticipated that pharmacological inhibition of ATR might not be
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knockout inmice leads to early embryonic lethality (Brown&Baltimore,
2000; de Klein et al., 2000). In humans, mutations in ATR lead to a rare
hereditary disorder, Seckel syndrome (O'Driscoll et al., 2003; Alderton
et al., 2004). However, the ATR mutations causing Seckel syndrome
are hypomorphic, with only a partial loss of gene function. While there
are numerous human hereditary diseases which are caused by a loss of
protein expression of DDR proteins like ATM (ataxia–telangiectasia) or
NBS1 (Nijmegen breakage syndrome), it appears that mutations in ATR
are only compatible with viability when heterozygous or hypomorphic.
This further supports the concept that some ATR function is essential
for the development and viability of multicellular organisms.
Furthermore, ATR activity is required in all proliferating cells during
normal S-phase to ensure proper DNA replication and maintenance of
genomic stability. Ruzankina et al. demonstrated that depletion of ATR
in adultmice leads to defects in tissue homeostasis through acute cellular
loss in tissues in which continuous cell proliferation is required for
maintenance (Ruzankina et al., 2007). Furthermore, in a mouse model
of Seckel syndrome, the partial loss of ATR leads to the induction of
substantial replication stress, leading to accelerated ageing thereby
limiting the lifespan of the mice (Murga et al., 2010). These observations
may be explained by the fact, that even in the absence of replication
stress-inducing agents, some replication fork stalling can occur during
normal replication, for example at common fragile sites or repetitive
sequences (Mirkin & Mirkin, 2007). Common fragile sites are large
chromosomal regions that are thought to be particularly difﬁcult to
replicate. It has been shown that ATR is critical for fragile-site stability
and that ATR-deﬁcient cells have high levels of fragile site breakage
resulting in the induction of DNA double strand breaks (Casper et al.,
2002). This ﬁnding is consistent with the observation that ATR knock-
out leads to chromosomal fragmentation and cell death which are
thought to be the underlying reason for embryonic lethality (Brown &
Baltimore, 2000). The observed impediments of normal DNA replication
and induction of DNADSBs following ATR depletion raise the possibility
that pharmacological ATR inhibition could cause severe side effects
due to toxicity on highly proliferative normal tissues, especially if ATR
inhibition was combined with drugs that cause replication stress.
However, several studies have indicated that ATR inhibition might be
preferentially cytotoxic for cancer cells, thereby raising the possibility
of a therapeutic window for ATR inhibitors in cancer therapy. A recent
study in a mouse model of Seckel syndrome demonstrated that the
detrimental effects of ATR-deﬁciency on cell viabilitymay be ameliorated
by p53 since loss of p53 function exacerbated the accumulation of
replication stress when ATR signalling was compromised (Murga et al.,
2010). Functional loss of p53 was also found to profoundly aggravate
the severity of ATR loss in adult mice. Simultaneous depletion of p53
and ATR exacerbated tissue degeneration, accompanied by the induction
of high levels of DNA damage, and accelerated lethality of the mice
(Ruzankina et al., 2009). These ﬁndings point towards an important
role of p53 in the cellular response to ATR inhibition and raise
the possibility that p53-deﬁcient tumours, which comprise a high
proportion of cancer cases, may show increased sensitivity to ATR
inhibition compared with non-tumour tissue.
Several studies have demonstrated that depletion of functional ATR
increases the sensitivity of cancer cells to oncogene-induced replication
stress thereby hindering tumour growth and inducing extensive cell
death (Gilad et al., 2010; Murga et al., 2011; Schoppy et al., 2012).
Importantly, Schoppy et al. found that hypomorphic ATR signalling
(reduced to 10% of normal levels) was sufﬁcient to induce synthetic
lethality in oncogenic RAS-driven tumours, while only minimally
affecting normal bone marrow and intestinal homeostasis (Schoppy
et al., 2012). This ﬁnding suggests that a low level of ATR activity may
be sufﬁcient to sustain viability of highly proliferative adult tissues
and at the same time raises the possibility that complete inhibition
of ATR kinase activity may not be required to cause substantial and
selective toxicity in cancer cells.Most tumour cells are defective in the DNA damage induced G1
cell-cycle checkpoint through, for example, mutations in p53 or other
components of the p53 pathway. This leads to a reliance of the cells on
the intra-S-phase and G2/M checkpoints to arrest the cell cycle following
DNA damage induction to allow for repair of the damage and
consequently cell survival (Kastan et al., 1992). Inhibition of ATR,
which is an important mediator of the intra-S-phase and G2/M cell
cycle arrest in such cells would therefore lead to a general loss of
DNA damage checkpoints, causing DNA damage accumulation and
pre-mature entry into mitosis leading to mitotic catastrophe and cell
death. G1 checkpoint-proﬁcient cells, however, would be spared.
Several proof-of-principle studies utilising expression of kinase dead
ATR protein have demonstrated that functional loss of ATR leads to
abrogation of the DNA damage-induced G2/M cell cycle arrest and
sensitisation of cells to IR and a variety of DNAdamaging chemotherapeu-
tic agents (Cliby et al., 1998; Nghiem et al., 2002; Caporali et al., 2004).
Indeed, caffeine, an inhibitor of both ATM and ATR, sensitises cells to IR
and provides further support to these ﬁndings (Blasina et al., 1999;
Sarkaria et al., 1999). Overall, these data encouraged the search for, and
the development of, more potent and selective ATR inhibitors (Table 2).
The ﬁrst report on ATR-selective small-molecule inhibitors was pub-
lished in 2009. Nishida et al. reported that Schisandrin B, a naturally-
occurring dibenzocyclooctadiene lignan found in the medicinal herb
Schisandra chinensis was a selective inhibitor of ATR (Nishida et al.,
2009). The authors demonstrated that Schisandrin Bwas able to abrogate
UV-induced intra-S-phase and G2/M cell cycle checkpoints and increase
the cytotoxicity of UV radiation in human lung cancer cells. However,
the inhibitory potency against ATR was weak and required the use of
high drug concentrations (30 μM for cellular assays).
Amore potent ATR inhibitor, NU6027,was reported in 2011 andwas
demonstrated to sensitise several breast and ovarian cancer cell lines to
IR and several chemotherapeutic agents (Peasland et al., 2011). But, this
compound was originally developed as a CDK2 inhibitor and is not
selective for ATR.
Also in 2011, Toledo et al. reported the results of a cell-based
compound library screening approach for the identiﬁcation of potent
ATR inhibitors (Toledo et al., 2011). One of the compounds identiﬁed
to possess signiﬁcant inhibitory activity against ATR kinase was NVP-
BEZ235, a drug originally introduced as a highly potent dual inhibitor
of PI3K and MTOR with considerable in vivo anti-tumour activity
(Maira et al., 2008), NVP-BEZ235 has been demonstrated to markedly
radiosensitive Ras-overexpressing tumours (Konstantinidou et al.,
2010). However, in light of the ﬁnding that it also inhibits ATR (and to
a lesser extend ATM and DNA-PKcs), it seems likely that inhibition of
the DDR kinases rather than PI3K or MTOR contributed to the observed
effects. The aforementioned study by Gilad et al. which demonstrated
that ATR-depletion is particularly cytotoxicity in cells that overexpress
oncogenic Ras is in agreement with this notion (Gilad et al., 2010).
ETP-46464 and Torin 2 are additional examples of compounds which
possess potent ATR inhibitory activity, but lack selectivity (Liu et al.,
2011; Toledo et al., 2011).
A high-throughput screening campaign led to the discovery of the
ﬁrst series of both potent and selective ATR kinase inhibitors by Vertex
Pharmaceuticals (Charrier et al., 2011). One of these compounds, VE-
821, was shown to be a potent ATP-competitive inhibitor of ATRwith
minimal cross-reactivity against the related PIKKs ATM, DNA-PKcs
and MTOR (Reaper et al., 2011). VE-821 inhibited phosphorylation
of the ATR downstream target CHK1 at Ser345 and showed strong
synergy with genotoxic agents frommultiple classes in the colorectal
cancer cell line HCT116. The observed chemosensitisation was most
pronounced with DNA cross-linking agents such as cisplatin, and
was further enhanced by knockdown of p53 expression, in ATM-
deﬁcient cells or in combination with the speciﬁc ATM inhibitor
KU-55933. Importantly, VE-821 cytotoxicity in normal cells
appeared minimal, causing only a reversible growth arrest without
signiﬁcant induction of cell death (Reaper et al., 2011). These ﬁndings
Table 2
ATR inhibitors.
Compound Targets Description References
Schisandrin B ATR Selective, though weak ATR inhibitor. Abrogates the UV-induced S and G2/M cell
cycle checkpoints and increases sensitivity of cancer cells to UV radiation
Nishida et al., 2009
NU6027 CDK2, ATR NU6027 was originally developed as CDK2 inhibitor, but also potently inhibits ATR
activity. Has been demonstrated to chemo- and radiosensitise several breast and
ovarian cancer cell lines
Peasland et al., 2011
NVP-BEZ235 PI3K,MTOR,
ATR, ATM,
DNA-PKcs
Originally developed as dual PI3K/MTOR inhibitor, also possesses substantial activity
against ATM, ATR, and DNA-PKcs. Has been demonstrated to potently radiosensitise
RAS-overexpressing tumours
Maira et al., 2008; Toledo et al., 2011
Konstantinidou et al., 2010
VE-821 ATR First potent and selective ATR inhibitor. Chemosensitises cancer cells to various
chemotherapeutics in vitro. Chemosensitisation most potent for cross-linking
agents. Potent in vitro radiosensitiser. Shows increased single-agent toxicity in
hypoxic cells
Charrier et al., 2011; Reaper et al., 2011; Pires
et al., 2012; Prevo et al., 2012; Huntoon et al.,
2013
VE-822 (VX-970) ATR Analogue of VE-821 with increased potency and improved bioavailability. First ATR
inhibitor to enter clinical development.
Increased anti-tumour activity with IR and gemcitabine in xenograft models of
pancreatic cancer. Chemosensitises lung cancer cells to several chemotherapeutic
drugs in vitro. Increases the anti-tumour activity of cisplatin in vivo
Fokas et al., 2012; Hall et al., 2014
ClinicalTrials.gov: NCT02157792
AZ20 ATR Potent and selective ATR inhibitor. Possesses substantial single agent activity against
MRE11-deﬁcient cancer cells in vivo at well tolerated doses
Jacq et al., 2012; Foote et al., 2013
AZD6738 ATR Analogue of AZ20 with improved solubility, pharmacodynamics and bioavailability.
Signiﬁcantly increases anti-tumour activity of IR or carboplatin in vivo. Shows
single-agent activity in ATM-deﬁcient xenograft models. Currently in Phase I clinical
development
Guichard et al., 2013; Jones et al., 2013
ClinicalTrials.gov: NCT02223923
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demonstrated that genetic inhibition of ATR expression selectively
enhanced cisplatin sensitivity in human colorectal cancer cells with
inactivated p53 (Sangster-Guity et al., 2011).
Together these studies further promote the concept that G1
checkpoint-deﬁcient cancer cells might be more sensitive ATR kinase
inhibition, especially in combination with genotoxic treatments. VE-
821 has since been used in several studies and has consistently been
shown to sensitise a variety of cancer cell lines to IR and chemotherapy
(Pires et al., 2012; Prevo et al., 2012; Huntoon et al., 2013). Pires et al.
demonstrated, that VE-821 enhanced IR-induced cytotoxicity in a
panel of 12 human cancer cell lines. Notably, VE-821 radiosensitised
cancer cells under severe hypoxia and over a range of oxygen
concentrations (Pires et al., 2012). This is of particular interest, as
hypoxic tumour cells are more resistant to radiotherapy (Wouters &
Brown, 1997; Sprong et al., 2006) and therefore represent a major
obstacle for the efﬁcacy of radiotherapy. However, whether such a
strategy is also effective in vivo is yet to be demonstrated.
VE-822, an analogue of VE-821with increased potency and selectivity
against ATR, increased solubility and good pharmacokinetic properties
was shown to potently radiosensitise pancreatic cancer cell lines
in vitro. Furthermore, VE-822 treatment profoundly radiosensitised
xenograft models of human pancreatic cancer and further increased
the growthdelay inducedby IR combinedwith gemcitabine. Importantly,
VE-822waswell tolerated inmice anddid not enhance toxicity in normal
cells and tissues (Fokas et al., 2012). VE-822 was the ﬁrst selective ATR
inhibitor to enter clinical development, and is now known as VX-970.In a recent study, published by Vertex Pharmaceuticals, VX-970
(VE-822) was shown to markedly sensitise a panel of non-small cell
lung cancer cell lines, but not normal cells, to multiple DNA damaging
drugs, namely cisplatin, oxaliplatin, gemcitabine, etoposide and SN38,
the active metabolite of irinotecan. The sensitising effect of VX-970
was most evident with cisplatin and gemcitabine co-treatment, where
N75% of the 35 tested cell lines were sensitised. Consistent with previous
reports, the observed chemosensitisation was more pronounced in cells
with p53-deﬁciency than in cells with retained p53 activity. In patient-
derived lung tumour xenograft models, VX-970 signiﬁcantly improved
responses to cisplatin (in six out of the seven models) (Hall et al.,
2014). These data suggest that VX-970 may have the potential to
increase the efﬁcacy of DNA damaging therapy in patients with lung
cancer. A phase I clinical trial to assess the safety, tolerability and
pharmacokinetics of VX-970 in combination with cytotoxic chemo-
therapy is currently ongoing (ClinicalTrials.gov: NCT02157792).
A second ATR inhibitor currently in clinical development is AZD6738,
developed by AstraZeneca. AZD6738 is an analogue of AZ20, a potent and
selective ATR inhibitor which has been shown to possess substantial
in vivo single agent activity in MRE11A-deﬁcient LoVo xenografts at
well tolerated doses (Jacq et al., 2012; Foote et al., 2013). AZD6738
possesses signiﬁcantly improved solubility, bioavailability and pharmaco-
kinetic properties compared to AZ20 and is suitable for oral dosing (Jones
et al., 2013). It inhibits phosphorylation of the ATR downstream target
CHK1 while increasing phosphorylation of the DNA DSB marker γH2AX
in vitro. In vivo combination studies with carboplatin or IR demonstrated
signiﬁcantly increased anti-tumour growth inhibitory activity with this
Table 3
Potential biomarkers in the development of ATM and ATR inhibitors.
Patient selection Target
inhibition
Pathway modulation
Over-expression of components of
DDR pathwaya
DDR defects (intrinsic)
– ATMb
– p53b
– FANCD2c
– XRCC1d
– MRE11Ae
DDR defects (conditional)
– Hypoxiaf
Replication stress
– Activating oncogenes
(e.g. Ras, Myc)g
– pATMh
– pKAP1h
– pSMC1i
– pTP53h
– γH2AXj
– pCHK1b
– Dysfunctional cell cycle arrestk
– Unrepaired DNA DSBsl
– Increased
– DNA replication stressm
– Premature mitosis and mitotic
catastrophen
a Bao et al. (2006).
b Reaper et al. (2011).
c Kennedy et al. (2007).
d Sultana et al. (2013a, 2013b).
e Foote et al. (2013).
f Pires et al. (2012).
g Gilad et al. (2010), Schoppy et al. (2012), Murga et al. (2011).
h Guo et al. (2014).
i Kitagawa et al. (2004).
j Burma et al. (2001).
k Cliby et al. (1998)
l Kühne et al. (2004).
m Murga et al. (2011).
n Blasina et al. (1999).
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activity in ATM-deﬁcient but not ATM-proﬁcient xenograft models
(Guichard et al., 2013; Jones et al., 2013). This anti-tumour activity
was associated with a persistent increase in γH2AX staining in tumour
tissue but only a transient increase in normal tissues such as bone
marrow or gut. This suggests that a favourable therapeutic index could
be achieved, which is encouraging for the further development of this
compound for the clinic. A phase I clinical trial to assess the safety of
AZD6738 alone and in combination with radiotherapy in patients with
solid tumours is currently recruiting (ClinicalTrials.gov: NCT02223923).
8. Synthetic lethal approaches
In addition to the potential utility of ATM and ATR as chemo- or
radiosensitisers, recent studies suggest that such compounds may
have single agent activity in certain subsets of patients through induction
of synthetic lethality. Two genes are considered synthetically lethal, if
mutationor inactivation of either geneor gene product alone has no effect
on cellular viability, whereas simultaneous defects in both genes/gene
products lead to cell death (Kaelin, 2005).
The observed single-agent anti-tumour activity of AZD6738 in ATM-
deﬁcient but not ATM-proﬁcient xenograft models suggests that such a
synthetic lethal interaction could exist between the ATM and ATR
signalling pathways (Guichard et al., 2013; Jones et al., 2013), potentially
due to the overlapping and cooperating roles of these pathways in
coordinating cell cycle progression with DNA repair. In our own studies
we were able to show that non-small cell lung cancer cells deﬁcient in
both ATM and p53 are particularly sensitive to ATR inhibition in vitro,
suggesting that the functional status of p53maybe important in this set-
ting aswell (Weber et al., 2013). Similarly, PARP inhibitors possess single
agent activity in ATM-deﬁcient tumour cells in vitro and in vivo
(Aguilar-Quesada et al., 2007; Weston et al., 2010; Williamson et al.,
2010). However, the cytotoxicity of PARP inhibitors was shown
to be enhanced when the function of both ATM and p53 was lost
(Williamson et al., 2012; Kubota et al., 2014).
Several putative synthetic lethal interactions between the ATM or
ATR signalling pathways andotherDDR components have been reported.
Inhibition or knockdown of ATM has been shown to be synthetically
lethal in cells with defects in the Fanconi anaemia pathway, components
of which are commonly mutated or lost in cancer (Kennedy & D'Andrea,
2006; Kennedy et al., 2007). ATM inhibition or -deﬁciency has also been
shown to be synthetically lethal in combination with APE1 inhibitors
(Sultana et al., 2012) or functional loss of XRCC1 (Sultana et al., 2013a),
which is frequently deregulated in breast and ovarian cancers (Abdel-
Fatah et al., 2013; Sultana et al., 2013a). ATR inhibition has been
shown to be synthetically lethal with XRCC1 or ERCC1 loss (Sultana
et al., 2013a; Mohni et al., 2014). Furthermore, the observed increased
cytotoxicity of the ATR inhibitors AZ20 and AZD6738 in MRE11A
mutated LoVo cells in vitro and in vivo (Jacq et al., 2012; Foote et al.,
2013; Guichard et al., 2013) points towards a potential synthetic lethal
interaction between ATR inhibition and functional loss of MRE11. This
synthetic lethality may include other components of the MRN complex
as well (Al-Ahmadie et al., 2014). Hence, pharmaceutical inhibition of
ATM and/or ATR may provide the basis for the selective treatment of
DDR pathway-deﬁcient cancers.
9. Biomarkers and patient selection
To increase the success rate for drug development it has been
proposed that biomarkers to identify patient subgroups likely to get the
greatest beneﬁt from new drugs should be identiﬁed early, alongside
biomarkers of target inhibition (pharmacodynamic; PD), pathway
modulation, and anticipated biological effect(s) (Yap et al., 2010).
Although patient selection biomarkers for ATM and ATR inhibitors
have not yet been established, published in vitro and in vivo data
suggest a number of potential strategies (Table 3). Increased tumourDDR capacity has been associated with resistance to radio- and chemo-
therapies, for example by upregulating DNA repair capacity in response
to platinum-based therapy (Martin et al., 2008; Oliver et al., 2010).
Although resistance to therapy is likely to be multifactorial and highly
dependent on the particular therapy under consideration (e.g. cisplatin,
taxanes, radiation), conceptually, a test for increased tumour DDR
capacity might identify a group of patients who would gain particular
beneﬁt from combination therapy with either an ATM or ATR inhibitor.
Interestingly, elevated levels of phospho-ATM (Ser1981) prior to radio-
therapy has been associated with radioresistance and poor prognosis in
cervical cancer (Roossink et al., 2012). This suggests that levels of ATM
autophosphorylation in tumour tissues could serve as a potential
biomarker to identify patients that might get the greatest beneﬁt from
a combination of ATM inhibitor treatment and radiotherapy. As outlined
above, many human tumours acquire defects in the DDR in order to
tolerate DNA replication stress and genomic instability that are
characteristic of oncogene activation during cancer development.
These DDR defects offer the potential to use ATM or ATR inhibition
as a synthetic lethal approach, in an analogous manner to the use
of PARP inhibitors in BRCA1/2 defective tumours. Functional defects
in several components of the DDR pathway have been reported to confer
sensitivity to ATM and/or ATR inhibition, including p53 (Reaper et al.,
2011), XRCC1 (Sultana et al., 2013a, 2013b), FANCD2 (Kennedy et al.,
2007), MRE11A (Jacq et al., 2012; Foote et al., 2013; Guichard et al.,
2013), RAD50 (Al-Ahmadie et al., 2014), BRCA1 (Albarakati et al., 2014)
and ATM (Reaper et al., 2011). Whole exome/genome sequencing offers
a potential method to identify patient subgroups or particular cancer
types with DDR defects (Kandoth et al., 2013), although the relationships
between reported mutations and loss of protein function for many of the
DDR proteins have yet to be determined. Of the DDR genes, p53 is the
most widely studied with an extensive literature on the functional
consequences of a wide range of mutations (Petitjean et al., 2007).
Therefore, p53 mutation status may provide an enrichment strategy
for selecting patients for treatment with ATM or ATR inhibitors, but
p53 status remains a complex biomarker to interpret (Olivier et al.,
2010).
It has also been reported that defects in ATM or ATR signalling are
synthetically lethal with PARP inhibition (Turner et al., 2008; Peasland
134 A.M. Weber, A.J. Ryan / Pharmacology & Therapeutics 149 (2015) 124–138et al., 2011; Yap et al., 2011; Michels et al., 2014), suggesting that
combined inhibition of PARP and ATM or ATR may be an effective
therapeutic strategy. In addition to intrinsic defects in DDR, tumour
cells may also acquire conditional DDR defects. Under hypoxic
conditions, the expression of several proteins involved in homologous
recombination is down-regulated, conferring sensitivity to ATR inhibition
(Chan et al., 2010; Pires et al., 2012). Potentially, patient subgroups with
high levels of tumour hypoxia could be identiﬁed by immunohistochem-
istry (Loncaster et al., 2001), using gene expression arrays (Eustace et al.,
2013), or by non-invasive imaging (e.g. with 18F-Misonidazole PET
(Eschmann et al., 2005)).
In the early stages of clinical development, it is crucial to demonstrate
that a new drug inhibits its target sufﬁciently to modulate relevant path-
ways to elicit a biological response. For ATM inhibitors, a number of
potential measures of target inhibition have been identiﬁed, including
ATM autophosphorylation, or phosphorylation of the ATM downstream
targets p53, KAP1, SMC1, CHK2, and H2AX (γH2AX) (Shiloh & Ziv,
2013; Guo et al., 2014). A caveat is that several of thesemarkers, including
p53 and γH2AX are not speciﬁc measures of ATM kinase activity as
they may also be targets of other kinases, including DNA-PKcs and ATR
(Hammond et al., 2003; Mukherjee et al., 2006). The use of a panel of
these markers is likely to be most informative in evaluating the activity
of ATM inhibitors in the clinic (Bartkova et al., 2005; Kozlov et al., 2011).
CHK1 phosphorylation is themost widely used preclinical biomarker
of ATR kinase activity (Fokas et al., 2012; Pires et al., 2012; Hall et al.,
2014). However, ATM can also phosphorylate CHK1 (Gatei et al., 2003;
Sørensen et al., 2003; Helt et al., 2005), albeit to a lesser extent and a
recent study in ovarian cancer has suggested that CHK1phosphorylation
status may not offer a reliable marker for inhibition of the ATR-CHK1
pathway (Huntoon et al., 2013). Other, less direct, measures of ATR
inhibitor activity could include increased DNA replication stressmarkers
such as pan-nuclear γH2AX (Jacq et al., 2012; Foote et al., 2013;
Guichard et al., 2013; Jones et al., 2013) or nuclear foci staining of RPA
or RAD51, a marker for homologous recombination repair, but these
are unlikely to be speciﬁc pathway markers of ATR inhibition.
Finally, the biological consequence of ATM/ATR target and pathway
inhibition, either in combination with genotoxic therapy, or as a
synthetic lethal monotherapy in DDR-defective tumours is selective
tumour cell deathwhichwouldbe expected to produce tumour shrinkage
in the clinical setting measurable by standard RECIST criteria (Fojo &
Noonan, 2012) with the potential for assessing early circulating markers
of apoptosis (Ward et al., 2008).
10. Conclusion
A broad range of preclinical research and an extensive literature of
underpinning science support the development of ATM and ATR kinase
inhibitors in two distinct clinical settings— as amonotherapy aiming for
synthetic lethal responses in tumours with intrinsic or conditional DDR
defects, and in combination with chemo- or radiotherapy. Each setting
has distinct challenges. Identifying the right patients will be critical if
the synthetic lethal strategy is to be successful. Current sequencing
techniques can identify mutations in DDR genes that may impact on
the response of cancer cells to ATM or ATR inhibitors. However, without
functional studies, the consequences of these mutations are difﬁcult to
predict for proteins such as, for example, ATM, MRE11, RAD50 or
FANCD. In addition, DDR defects may arise by epigenetic and/or post-
transcriptional mechanisms. Developing biomarkers that can robustly
determine the functional status of DDR pathways in tumours and help
differentiate between deleterious and benign mutations will therefore
be essential.
For combination studies, a key issue is likely to be concern over
the potential for increased normal tissue toxicity, and identifying the
combinations and schedules that have the greatest potential for tumour
selective effects is a priority area of research that needs further investiga-
tion. SelectiveATR inhibitors are currently in Phase 1 clinical developmentand it seems likely that ATM inhibitors with good pharmacological
properties will become available in the near future. Notably, inhibitors
of other DDR targets including PARP, CHK1/2, WEE1, and DNA-PKcs
are also in clinical development and it will be of great interest to follow
the progress of these approaches and to use the emerging results to
better guide the future clinical development of ATM and ATR inhibitors.
Conﬂict of interest
The authors declare that there are no conﬂicts of interest.
Acknowledgments
Thisworkwas supported by grants from theMedical Research Council
(UK) (A.J.R.) (MC_PC_12006) and Cancer Research UK (A.M.W.) (18443)
The funding bodies had no involvement in thewriting of this review or in
the decision to submit for publication.
References
Abdel-Fatah, T., Sultana, R., Abbotts, R., Hawkes, C., Seedhouse, C., Chan, S., et al. (2013).
Clinicopathological and functional signiﬁcance of XRCC1 expression in ovarian cancer.
Int J Cancer 132, 2778–2786.
Abraham, R. T. (2001). Cell cycle checkpoint signaling through the ATM and ATR kinases.
Genes Dev 15, 2177–2196.
Aguilar-Quesada, R., Muñoz-Gámez, J. A., Martín-Oliva, D., Peralta, A., Valenzuela, M. T.,
Matínez-Romero, R., et al. (2007). Interaction between ATM and PARP-1 in response
to DNA damage and sensitization of ATM deﬁcient cells through PARP inhibition.
BMC Mol Biol 8, 29.
Al-Ahmadie, H., Iyer, G., Hohl, M., Asthana, S., Inagaki, A., Schultz, N., et al. (2014). Synthetic
lethality in ATM-deﬁcient RAD50-mutant tumors underlie outlier response to cancer
therapy. Cancer Discov 4, 1014–1021.
Albarakati, N., Abdel-Fatah, T. M. A., Doherty, R., Russell, R., Agarwal, D., Moseley, P., et al.
(2014). Targeting BRCA1-BER deﬁcient breast cancer by ATM or DNA-PKcs blockade
either alone or in combination with cisplatin for personalized therapy. Mol Oncol.
http://dx.doi.org/10.1016/j.molonc.2014.08.001.
Alderton, G. K., Joenje, H., Varon, R., Børglum, A. D., Jeggo, P. A., & O'Driscoll, M. (2004).
Seckel syndrome exhibits cellular features demonstrating defects in the ATR-
signalling pathway. Hum Mol Genet 13, 3127–3138.
Audeh,M.W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M.,
et al. (2010). Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with
BRCA1 or BRCA2 mutations and recurrent ovarian cancer: A proof-of-concept trial.
Lancet 376, 245–251.
Bakkenist, C. J., & Kastan, M. B. (2003). DNA damage activates ATM through intermolecular
autophosphorylation and dimer dissociation. Nature 421, 499–506.
Banin, S., Moyal, L., Shieh, S. -Y., Taya, Y., Anderson, C. W., Chessa, L., et al. (1998).
Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science 281,
1674–1677.
Bao, S., Wu, Q., McLendon, R. E., Hao, Y., Shi, Q., Hjelmeland, A. B., et al. (2006). Glioma stem
cells promote radioresistance by preferential activation of the DNA damage response.
Nature 444, 756–760.
Barlow, C., Hirotsune, S., Paylor, R., Liyanage, M., Eckhaus, M., Collins, F., et al. (1996).
Atm-deﬁcient mice: A paradigm of ataxia telangiectasia. Cell 86, 159–171.
Bartek, J., Lukas, C., & Lukas, J. (2004). Checking on DNA damage in S phase. Nat Rev Mol
Cell Biol 5, 792–804.
Bartkova, J., Horejsi, Z., Koed, K., Krämer, A., Tort, F., Zieger, K., et al. (2005). DNA damage
response as a candidate anti-cancer barrier in early human tumorigenesis. Nature
434, 864–870.
Bartkova, J., Rezaei, N., Liontos, M., Karakaidos, P., Kletsas, D., Issaeva, N., et al. (2006).
Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA
damage checkpoints. Nature 444, 633–637.
Bartkova, J., Tommiska, J., Oplustilova, L., Aaltonen, K., Tamminen, A., Heikkinen, T., et al.
(2008). Aberrations of the MRE11–RAD50–NBS1 DNA damage sensor complex in
human breast cancer: MRE11 as a candidate familial cancer-predisposing gene. Mol
Oncol 2, 296–316.
Batey, M. A., Zhao, Y., Kyle, S., Richardson, C., Slade, A., Martin, N. M. B., et al. (2013).
Preclinical evaluation of a novel ATM inhibitor, KU59403, in vitro and in vivo in p53
functional and dysfunctional models of human cancer. Mol Cancer Ther 12, 959–967.
Beà, S., Valdés-Mas, R., Navarro, A., Salaverria, I., Martín-Garcia, D., Jares, P., et al. (2013).
Landscape of somatic mutations and clonal evolution in mantle cell lymphoma. Proc
Natl Acad Sci U S A 110, 18250–18255.
Bennett, C. B., Lewis, A. L., Baldwin, K. K., & Resnick, M. A. (1993). Lethality induced by a
single site-speciﬁc double-strand break in a dispensable yeast plasmid. Proc Natl
Acad Sci U S A 90, 5613–5617.
Bennetzen, M. V., Larsen, D. H., Bunkenborg, J., Bartek, J., Lukas, J., & Andersen, J. S. (2010).
Site-speciﬁc phosphorylation dynamics of the nuclear proteome during the DNA
damage response. Mol Cell Proteomics 9, 1314–1323.
Bensimon, A., Schmidt, A., Ziv, Y., Elkon, R., Wang, S. -Y., Chen, D. J., et al. (2010).
ATM-dependent and -independent dynamics of the nuclear phosphoproteome after
DNA damage. Sci Signal 3, rs3.
135A.M. Weber, A.J. Ryan / Pharmacology & Therapeutics 149 (2015) 124–138Bi, X., Srikanta, D., Fanti, L., Pimpinelli, S., Badugu, R., Kellum, R., et al. (2005). Drosophila
ATM and ATR checkpoint kinases control partially redundant pathways for telomere
maintenance. Proc Natl Acad Sci U S A 102, 15167–15172.
Biddlestone-Thorpe, L., Sajjad, M., Rosenberg, E., Beckta, J. M., Valerie, N. C. K., Tokarz, M.,
et al. (2013). ATM kinase inhibition preferentially sensitizes p53-mutant glioma to
ionizing radiation. Clin Cancer Res 19, 3189–3200.
Blasina, A., Hallin, J., Chen, E., Arango, M. E., Kraynov, E., Register, J., et al. (2008).
Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule
inhibitor of checkpoint kinase 1. Mol Cancer Ther 7, 2394–2404.
Blasina, A., Price, B. D., Turenne, G. A., & McGowan, C. H. (1999). Caffeine inhibits the
checkpoint kinase ATM. Curr Biol 9, 1135–1138.
Bobola, M. S., Kolstoe, D. D., Blank, A., Chamberlain, M. C., & Silber, J. R. (2012). Repair
of 3-methyladenine and abasic sites by base excision repair mediates glioblastoma
resistance to temozolomide. Front Oncol 2, 176.
Bosotti, R., Isacchi, A., & Sonnhammer, E. L. (2000). FAT: A novel domain in PIK-related
kinases. Trends Biochem Sci 25, 225–227.
Bracey, T. S., Williams, A. C., & Paraskeva, C. (1997). Inhibition of radiation-induced G2
delay potentiates cell death by apoptosis and/or the induction of giant cells in colorectal
tumor cells with disrupted p53 function. Clin Cancer Res 3, 1371–1381.
Brown, E. J., & Baltimore, D. (2000). ATR disruption leads to chromosomal fragmentation
and early embryonic lethality. Genes Dev 14, 397–402.
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., et al. (2005).
Speciﬁc killing of BRCA2-deﬁcient tumours with inhibitors of poly(ADP-ribose)
polymerase. Nature 434, 913–917.
Burma, S., Chen, B. P., Murphy, M., Kurimasa, A., & Chen, D. J. (2001). ATM phosphorylates
histone H2AX in response to DNA double-strand breaks. J Biol Chem 276,
42462–42467.
Byun, T. S., Pacek, M., Yee, M., Walter, J. C., & Cimprich, K. A. (2005). Functional uncoupling of
MCM helicase and DNA polymerase activities activates the ATR-dependent checkpoint.
Genes Dev 19, 1040–1052.
Cancer Genome Atlas Research Network (2012a). Comprehensive molecular
characterization of human colon and rectal cancer. Nature 487, 330–337.
Cancer Genome Atlas Research Network (2012b). Comprehensive genomic characterization
of squamous cell lung cancers. Nature 489, 519–525.
Cancer Genome Atlas Research Network (2012c). Comprehensive molecular portraits of
human breast tumours. Nature 490, 61–70.
Cancer Genome Atlas Research Network (2014). Comprehensive molecular proﬁling of
lung adenocarcinoma. Nature 511, 543–550.
Canman, C. E., Lim, D. -S., Cimprich, K. A., Taya, Y., Tamai, K., Sakaguchi, K., et al. (1998).
Activation of the ATM kinase by ionizing radiation and phosphorylation of p53.
Science 281, 1677–1679.
Caporali, S., Falcinelli, S., Starace, G., Russo, M. T., Bonmassar, E., Jiricny, J., et al. (2004).
DNA damage induced by temozolomide signals to both ATM and ATR: Role of the
mismatch repair system. Mol Pharmacol 66, 478–491.
Casper, A. M., Nghiem, P., Arlt, M. F., & Glover, T. W. (2002). ATR regulates fragile site
stability. Cell 111, 779–789.
Chan, N., Pires, I. M., Bencokova, Z., Coackley, C., Luoto, K. R., Bhogal, N., et al. (2010).
Contextual synthetic lethality of cancer cell kill based on the tumor microenvironment.
Cancer Res 70, 8045–8054.
Charrier, J. -D., Durrant, S. J., Golec, J. M. C., Kay, D. P., Knegtel, R. M. A., MacCormick, S.,
et al. (2011). Discovery of potent and selective inhibitors of ataxia telangiectasia
mutated and Rad3 related (ATR) protein kinase as potential anticancer agents.
J Med Chem 54, 2320–2330.
Chehab, N. H., Malikzay, A., Appel, M., & Halazonetis, T. D. (2000). Chk2/hCds1 functions
as a DNA damage checkpoint in G1 by stabilizing p53. Genes Dev 14, 278–288.
Chehab, N. H., Malikzay, A., Stavridi, E. S., & Halazonetis, T. D. (1999). Phosphorylation of
Ser-20 mediates stabilization of human p53 in response to DNA damage. Proc Natl
Acad Sci U S A 96, 13777–13782.
Chen, J. (2000). Ataxia telangiectasia-related protein is involved in the phosphorylation of
BRCA1 following deoxyribonucleic acid damage. Cancer Res 60, 5037–5039.
Choi, S., Gamper, A. M., White, J. S., & Bakkenist, C. J. (2010). Inhibition of ATM kinase
activity does not phenocopy ATM protein disruption: Implications for the clinical utility
of ATM kinase inhibitors. Cell Cycle 9, 4052–4057.
Choudhury, A., Nelson, L. D., Teo, M. T. W., Chilka, S., Bhattarai, S., Johnston, C. F., et al.
(2010). MRE11 expression is predictive of cause-speciﬁc survival following radical
radiotherapy for muscle-invasive bladder cancer. Cancer Res 70, 7017–7026.
Ciccia, A., & Elledge, S. J. (2011). The DNA damage response: Making it safe to play with
knives. Mol Cell 40, 179–204.
Cimprich, K., & Cortez, D. (2008). ATR: An essential regulator of genome integrity. Nat Rev
Mol Cell Biol 9, 616–627.
Cliby, W. A., Roberts, C. J., Cimprich, K. A., Stringer, C. M., Lamb, J. R., Schreiber, S. L., et al.
(1998). Overexpression of a kinase-inactive ATR protein causes sensitivity to
DNA-damaging agents and defects in cell cycle checkpoints. EMBO J 17, 159–169.
Cortez, D., Guntuku, S., Qin, J., & Elledge, S. J. (2001). ATR and ATRIP: Partners in checkpoint
signaling. Science 294, 1713–1716.
Dai, Y., & Grant, S. (2010). New insights into checkpoint kinase 1 in the DNA damage
response signaling network. Clin Cancer Res 16, 376–383.
De Klein, A., Muijtjens, M., van Os, R., Verhoeven, Y., Smit, B., Carr, A. M., et al. (2000).
Targeted disruption of the cell-cycle checkpoint gene ATR leads to early embryonic
lethality in mice. Curr Biol 10, 479–482.
Delacroix, S., Wagner, J. M., Kobayashi, M., Yamamoto, K., & Karnitz, L. M. (2007). The
Rad9–Hus1–Rad1 (9–1–1) clamp activates checkpoint signaling via TopBP1. Genes
Dev 21, 1472–1477.
Di Micco, R., Fumagalli, M., Cicalese, A., Piccinin, S., Gasparini, P., Luise, C., et al. (2006).
Oncogene-induced senescence is a DNA damage response triggered by DNA
hyper-replication. Nature 444, 638–642.Di Virgilio, M., Ying, C. Y., & Gautier, J. (2009). PIKK-dependent phosphorylation of Mre11
induces MRN complex inactivation by disassembly from chromatin. DNA Repair 8,
1311–1320.
Ditch, S., & Paull, T. T. (2012). The ATM protein kinase and cellular redox signaling:
Beyond the DNA damage response. Trends Biochem Sci 37, 15–22.
Ellison, V., & Stillman, B. (2001). Biochemical characterization of DNA damage checkpoint
complexes: Clamp loader and clamp complexes with speciﬁcity for 5′ recessed DNA.
PLoS Biol 1, 231–243.
Elson, A., Wang, Y., Daugherty, C. J., Morton, C. C., Zhou, F., Campos-Torres, J., et al. (1996).
Pleiotropic defects in ataxia–telangiectasia protein-deﬁcient mice. Proc Natl Acad Sci
U S A 93, 13084–13089.
Errico, A., & Costanzo, V. (2012). Mechanisms of replication fork protection: A safeguard
for genome stability. Crit Rev Biochem Mol Biol 47, 222–235.
Eschmann, S. -M., Paulsen, F., Reimold, M., Dittmann, H., Welz, S., Reischl, G., et al. (2005).
Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell
before radiotherapy. J Nucl Med 46, 253–260.
Eustace, A., Mani, N., Span, P. N., Irlam, J. J., Taylor, J., Betts, G. N. J., et al. (2013). A 26-gene
hypoxia signature predicts beneﬁt from hypoxia-modifying therapy in laryngeal
cancer but not bladder cancer. Clin Cancer Res 19, 4879–4888.
Falck, J., Mailand, N., Syljuåsen, R. G., Bartek, J., & Lukas, J. (2001). The ATM-Chk2-Cdc25A
checkpoint pathway guards against radioresistant DNA synthesis. Nature 410,
842–847.
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., et al.
(2005). Targeting theDNA repair defect in BRCAmutant cells as a therapeutic strategy.
Nature 434, 917–921.
Fernandes, N., Sun, Y., Chen, S., Paul, P., Shaw, R. J., Cantley, L. C., et al. (2005). DNA
damage-induced association of ATM with its target proteins requires a protein
interaction domain in the N terminus of ATM. J Biol Chem 280, 15158–15164.
Fojo, A. T., & Noonan, A. (2012).Why RECISTworks andwhy it should stay—Counterpoint.
Cancer Res 72, 5151–5157 (discussion 5158).
Fokas, E., Prevo, R., Pollard, J. R., Reaper, P. M., Charlton, P. A., Cornelissen, B., et al. (2012).
Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization
of pancreatic tumors to radiation. Cell Death Dis 3, e441.
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Marja, M. -R., et al. (2009). Inhibition of
poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med
361, 123–134.
Foote, K. M., Blades, K., Cronin, A., Fillery, S., Guichard, S. S., Hassall, L., et al. (2013). Discovery
of 4-{4-[(3R)-3-methylmorpholin-4-yl]-6-[1-(methylsulfonyl)cyclopropyl]pyrimidin-
2-yl}-1H-indole (AZ20): A potent and selective inhibitor of ATR protein kinase with
monotherapy in vivo antitumor activity. J Med Chem 56, 2125–2138.
Friesner, J. D., Liu, B., Culligan, K., & Britt, A. B. (2005). Ionizing radiation-dependent y-H2AX
focus formation requires ataxia telangiectasia mutated and ataxia telangiectasia
mutated and Rad3-related. Mol Biol Cell 16, 2566–2576.
Gatei, M., Jakob, B., Chen, P., Kijas, A. W., Becherel, O. J., Gueven, N., et al. (2011). ATM
protein-dependent phosphorylation of Rad50 protein regulates DNA repair and cell
cycle control. J Biol Chem 286, 31542–31556.
Gatei, M., Sloper, K., Sorensen, C., Syljuäsen, R., Falck, J., Hobson, K., et al. (2003). Ataxia–
telangiectasia-mutated (ATM) and NBS1-dependent phosphorylation of Chk1 on Ser-
317 in response to ionizing radiation. J Biol Chem 278, 14806–14811.
Gatei, M., Young, D., Cerosaletti, K. M., Desai-Mehta, A., Spring, K., Kozlov, S., et al. (2000).
ATM-dependent phosphorylation of nibrin in response to radiation exposure. Nat
Genet 25, 115–119.
Gilad, O., Nabet, B. Y., Ragland, R. L., Schoppy, D. W., Smith, K. D., Durham, A. C., et al.
(2010). Combining ATR suppression with oncogenic Ras synergistically increases
genomic instability, causing synthetic lethality or tumorigenesis in a dosage-
dependent manner. Cancer Res 70, 9693–9702.
Golding, S., Rosenberg, E., Adams, B. R., Wignarajah, S., Beckta, J. M., O'Connor, M. J., et al.
(2012). Dynamic inhibition of ATM kinase provides a strategy for glioblastoma
multiforme radiosensitization and growth control. Cell Cycle 11, 1167–1173.
Golding, S. E., Rosenberg, E., Valerie, N., Hussaini, I., Frigerio, M., Cockcroft, X. F., et al.
(2009). Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells,
compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration
and invasion. Mol Cancer Ther 8, 2894–2902.
Goode, E. L., Ulrich, C. M., & Potter, J. D. (2002). Polymorphisms in DNA repair genes and
associations with cancer risk. Cancer Epidemiol Biomarkers Prev 11, 1513–1530.
Gorgoulis, V. G., Vassiliou, L. F., Karakaidos, P., Zacharatos, P., Kotsinas, A., Liloglou, T., et al.
(2005). Activation of the DNA damage checkpoint and genomic instability in human
precancerous lesions. Nature 434, 907–913.
Graves, P. R., Lovly, C. M., Uy, G. L., & Piwnica-Worms, H. (2001). Localization of human
Cdc25C is regulated both by nuclear export and 14-3-3 protein binding. Oncogene
20, 1839–1851.
Guichard, S., Brown, E., Odedra, R., Hughes, A., Heathcote, D., Barnes, J., et al. (2013). The
pre-clinical in vitro and in vivo activity of AZD6738: A potent and selective inhibitor
of ATR kinase. (abstract) Proceedings of the 104th Annual Meeting of the American
Association for Cancer Research; 2013 Apr 6–10. Cancer Res. 73(8 Suppl.). Washington,
DC: AACR. http://dx.doi.org/10.1158/1538-7445.AM2013-3343 (Abstract nr 3343).
Guo, K., Shelat, A. a, Guy, R. K., & Kastan, M. B. (2014). Development of a cell-based, high-
throughput screening assay for ATM kinase inhibitors. J Biomol Screen 19, 538–546.
Halazonetis, T. D., Gorgoulis, V. G., & Bartek, J. (2008). An oncogene-induced DNA damage
model for cancer development. Science 319, 1352–1355.
Hall, A. B., Newsome, D., Wang, Y., Boucher, D. M., Eustace, B., Gu, Y., et al. (2014).
Potentiation of tumor responses toDNAdamaging therapy by the selective ATR inhibitor
VX-970. Oncotarget 5, 5674–5685.
Hammond, E. M., Dorie, M. J., & Giaccia, A. J. (2003). ATR/ATM targets are phosphorylated
by ATR in response to hypoxia and ATM in response to reoxygenation. J Biol Chem
278, 12207–12213.
136 A.M. Weber, A.J. Ryan / Pharmacology & Therapeutics 149 (2015) 124–138Hanahan, D., &Weinberg, R. A. (2011). Hallmarks of cancer: The next generation. Cell 144,
646–674.
Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997). Mdm2 promotes the rapid degradation
of p53. Nature 387, 296–299.
Helt, C. E., Cliby, W. A., Keng, P. C., Bambara, R. A., & O'Reilly, M. A. (2005). Ataxia tel-
angiectasia mutated (ATM) and ATM and Rad3-related protein exhibit selective
target speciﬁcities in response to different forms of DNA damage. J Biol Chem 280,
1186–1192.
Hickson, I., Zhao, Y., Richardson, C. J., Green, S. J., Martin, N. M. B., Orr, A. I., et al. (2004).
Identiﬁcation and characterization of a novel and speciﬁc inhibitor of the ataxia–
telangiectasia mutated kinase ATM. Cancer Res 64, 9152–9159.
Houldsworth, J., & Lavin, M. (1980). Effect of ionizing radiation on DNA synthesis in ataxia
telangiectasia cells. Nucleic Acids Res 8, 3709–3720.
Huntoon, C. J., Flatten, K. S., Wahner Hendrickson, A. E., Huehls, A. M., Sutor, S. L.,
Kaufmann, S. H., et al. (2013). ATR inhibition broadly sensitizes ovarian cancer cells
to chemotherapy independent of BRCA status. Cancer Res 73, 3683–3691.
Jackson, S. P., & Bartek, J. (2010). The DNA-damage response in human biology and disease.
Nature 461, 1071–1078.
Jacq, X., Smith, L., Brown, E., Hughes, A., Odedra, R., Heathcote, D., et al. (2012). AZ20, a
novel potent and selective inhibitor of ATR kinase with in vivo antitumour activity.
(abstract) Proceedings of the 103rd Annual Meeting of the American Association for
Cancer Research; 2012 Mar 31–Apr 4 Chicago. Cancer Res 72(8 Suppl.). IL Philadelphia
(PA): AACR. http://dx.doi.org/10.1158/1538-7445.AM2012-1823 (Abstract nr 1823).
Jacquemin, V., Rieunier, G., Jacob, S., Bellanger, D., D'Enghien, C. D., Laugé, A., et al. (2012).
Underexpression and abnormal localization of ATM products in ataxia telangiectasia
patients bearing ATM missense mutations. Eur J Hum Genet 20, 305–312.
Jones, C. D., Blades, K., Foote, K. M., Guichard, S. M., Jewsbury, Philip J., McGuire, T., et al.
(2013). Discovery of AZD6738, a potent and selective inhibitor with the potential to
test the clinical efﬁcacy ofATRkinase inhibition in cancer patients. (abstract) Proceedings
of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6–
10. Cancer Res 73(8 Suppl.). Washington, DC. Philadelphia (PA): AACR. http://dx.doi.org/
10.1158/1538-7445.AM2013-2348 (Abstract nr 2348).
Kaelin,W. G. J. (2005). The concept of synthetic lethality in the context of anticancer therapy.
Nat Rev Cancer 5, 689–698.
Kandoth, C., McLellan, M. D., Vandin, F., Ye, K., Niu, B., Lu, C., et al. (2013). Mutational
landscape and signiﬁcance across 12 major cancer types. Nature 502, 333–339.
Karnitz, L. M., Flatten, K. S., Wagner, J. M., Loegering, D., Hackbarth, J. S., Arlander, S. J. H.,
et al. (2005). Gemcitabine-induced activation of checkpoint signaling pathways that
affect tumor cell survival. Mol Pharmacol 68, 1636–1644.
Karve, S., Werner, M. E., Sukumar, R., Cummings, N. D., Copp, J. A., Wang, E. C., et al.
(2012). Revival of the abandoned therapeutic wortmannin by nanoparticle drug
delivery. Proc Natl Acad Sci U S A 109, 8230–8235.
Kastan, M. B., Zhan, Q., El-Deiry, W. S., Carrier, F., Jacks, T., Walsh, W. V., et al. (1992). A
mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in
ataxia–telangiectasia. Cell 71, 587–597.
Keith, C. T., & Schreiber, S. L. (1995). PIK-related kinases: DNA repair, recombination, and
cell cycle checkpoints. Science 270, 50–51.
Kennedy, R. D., Chen, C. C., Stuckert, P., Archila, E. M., De la Vega, M. A., Moreau, L. A., et al.
(2007). Fanconi anemia pathway-deﬁcient tumor cells are hypersensitive to inhibition
of ataxia telangiectasia mutated. J Clin Invest 117, 1140–1149.
Kennedy, R. D., & D'Andrea, A. D. (2006). DNA repair pathways in clinical practice:
Lessons from pediatric cancer susceptibility syndromes. J Clin Oncol 24,
3799–3808.
Khosravi, R., Maya, R., Gottlieb, T., Oren, M., Shiloh, Y., & Shkedy, D. (1999). Rapid ATM-
dependent phosphorylation of MDM2 precedes p53 accumulation in response to DNA
damage. Proc Natl Acad Sci U S A 96, 14973–14977.
Kim, S. -T., Lim, D. -S., Canman, C. E., & Kastan, M. B. (1999). Substrate speciﬁcities and
identiﬁcation of putative substrates of ATM kinase family members. J Biol Chem
274, 37538–37543.
Kim, W. -J., Vo, Q. N., Shrivastav, M., Lataxes, T. A., & Brown, K. D. (2002). Aberrant
methylation of the ATM promoter correlates with increased radiosensitivity in a
human colorectal tumor cell line. Oncogene 21, 3864–3871.
Kitagawa, R., Bakkenist, C. J., McKinnon, P. J., & Kastan, M. B. (2004). Phosphorylation of
SMC1 is a critical downstream event in the ATM–NBS1–BRCA1 pathway. Genes Dev
18, 1423–1438.
Konstantinidou, G., Bey, E. A., Rabellino, A., Schuster, K., Michael, S., Gazdar, A. F., et al.
(2010). Dual PI3K/mTOR blockade is an effective radiosensitizing strategy for the
treatment of non-small cell lung cancer harbouring K-RAS mutations. Cancer Res
69, 7644–7652.
Kozlov, S. V., Graham, M. E., Jakob, B., Tobias, F., Kijas, A. W., Tanuji, M., et al. (2011).
Autophosphorylation and ATM activation: Additional sites add to the complexity. J
Biol Chem 286, 9107–9119.
Kozlov, S. V., Graham, M. E., Peng, C., Chen, P., Robinson, P. J., & Lavin, M. F. (2006).
Involvement of novel autophosphorylation sites in ATM activation. EMBO J 25,
3504–3514.
Kubota, E., Williamson, C. T., Ye, R., Elegbede, A., Peterson, L., Lees-Miller, S. P., et al.
(2014). Low ATM protein expression and depletion of p53 correlates with olaparib
sensitivity in gastric cancer cell lines. Cell Cycle 13, 2129–2137.
Kühne, M., Riballo, E., Rief, N., Ku, M., Rothkamm, K., Jeggo, P. A., et al. (2004). A double-
strand break repair defect in ATM-deﬁcient cells contributes to radiosensitivity. Cancer
Res 64, 500–508.
Kumagai, A., & Dunphy, W. G. (1999). Binding of 14-3-3 proteins and nuclear export
control the intracellular localization of the mitotic inducer Cdc25. Genes Dev 13,
1067–1072.
Kumagai, A., Lee, J., Yoo, H. Y., & Dunphy, W. G. (2006). TopBP1 activates the ATR–ATRIP
complex. Cell 124, 943–955.Landau, D. A., &Wu, C. J. (2013). Chronic lymphocytic leukemia: Molecular heterogeneity
revealed by high-throughput genomics. Genome Med 5.
Lavin, M. F. (2008). Ataxia–telangiectasia: From a rare disorder to a paradigm for cell
signalling and cancer. Nat Rev Mol Cell Biol 9, 759–769.
Lavin, M. F., Scott, S., Gueven, N., Kozlov, S., Peng, C., & Chen, P. (2004). Functional conse-
quences of sequence alterations in the ATM gene. DNA Repair 3, 1197–1205.
Lee, J., Kumagai, A., & Dunphy, W. G. (2007). The Rad9–Hus1–Rad1 checkpoint clamp
regulates interaction of TopBP1 with ATR. J Biol Chem 282, 28036–28044.
Lee, J. -H., & Paull, T. T. (2005). ATM activation by DNA double-strand breaks through the
Mre11–Rad50–Nbs1 complex. Science 308, 551–554.
Lempiäinen, H., & Halazonetis, T. D. (2009). Emerging common themes in regulation of
PIKKs and PI3Ks. EMBO J 28, 3067–3073.
Levy-Lahad, E., & Friedman, E. (2007). Cancer risks among BRCA1 and BRCA2 mutation
carriers. Br J Cancer 96, 11–15.
Lim, D. -S., Kim, S. -T., Xu, B., Maser, R. S., Lin, J., Petrini, J. H. J., et al. (2000). ATM
phosphorylates p95/nbs1 in an S-phase checkpoint pathway. Nature 404, 613–617.
Lindahl, T., & Barnes, D. E. (2000). Repair of endogenous DNA damage. Cold Spring Harb
Symp Quant Biol 65, 127–133.
Lindhal, T. (1993). Instability and decay of the primary structure of DNA. Nature 362,
709–715.
Liu, Q., Wang, J., Kang, S. A., Thoreen, C. C., Ahmed, T., Sabatini, D. M., et al. (2011). Discovery
of 9-(6-aminopyridin-3-yl)-1-(3-(triﬂuoromethyl)phenyl)benzo[h][1,6]naphthyridin-
2(1H)-one (Torin2) as a potent, selective and orally available mTOR inhibitor for
treatment of cancer. J Med Chem 54, 1473–1480.
Loncaster, J. A., Harris, A. L., Davidson, S. E., Logue, J. P., Hunter, R. D., Wycoff, C. C., et al.
(2001). Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of
hypoxia: Correlations with tumor oxygen measurements and prognosis in locally
advanced carcinoma of the cervix. Cancer Res 61, 6394–6399.
Maira, S. -M., Stauffer, F., Brueggen, J., Furet, P., Schnell, C., Fritsch, C., et al. (2008).
Identiﬁcation and characterization of NVP-BEZ235, a new orally available dual
phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent
in vivo antitumor activity.Mol Cancer Ther 7, 1851–1863.
Marine, J. -C., & Lozano, G. (2010). Mdm2-mediated ubiquitylation: p53 and beyond. Cell
Death Differ 17, 93–102.
Martin, L. P., Hamilton, T. C., & Schilder, R. J. (2008). Platinum resistance: The role of DNA
repair pathways. Clin Cancer Res 14, 1291–1295.
Matsuoka, S., Ballif, B. A., Smogorzewska, A., McDonald, E. R., Hurov, K. E., Luo, J., et al. (2007).
ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA
damage. Science 316, 1160–1166.
Matsuoka, S., Huang, M., & Elledge, S. J. (1998). Linkage of ATM to cell cycle regulation by
the Chk2 protein kinase. Science 282, 1893–1897.
Matthews, D. J., Yakes, F. M., Chen, J., Tadano, M., Bornheim, L., Clary, D. O., et al. (2007).
Pharmacological abrogation of S-phase checkpoint enhances the anti-tumor activity
of gemcitabine in vivo. Cell Cycle 6, 104–110.
Michels, J., Vitale, I., Saparbaev, M., Castedo, M., & Kroemer, G. (2014). Predictive biomarkers
for cancer therapy with PARP inhibitors. Oncogene 33, 3894–3907.
Mirkin, E. V., & Mirkin, S. M. (2007). Replication fork stalling at natural impediments.
Microbiol Mol Biol Rev 71, 13–35.
Mitchell, J. B., Choudhuri, R., Fabre, K., Sowers, A. L., Citrin, D., Zabludoff, S. D., et al. (2010). In
vitro and in vivo radiation sensitization of human tumor cells by a novel checkpoint
kinase inhibitor, AZD7762. Clin Cancer Res 16, 2076–2084.
Mitui, M., Nahas, S. A., Du, L. T., Yang, Z., Lai, C. H., Nakamura, K., et al. (2009). Func-
tional and computational assessment of missense variants in the ataxia–telangi-
ectasia mutated (ATM) gene: Mutations with increased cancer risk. Hum Mutat
30, 12–21.
Mohni, K. N., Kavanaugh, G. M., & Cortez, D. (2014). ATR pathway inhibition is synthetically
lethal in cancer cells with ERCC1 deﬁciency. Cancer Res 74, 2835–2845.
Mukherjee, B., Kessinger, C., Kobayashi, J., Chen, B. P. C., Chen, D. J., Chatterjee, A., et al.
(2006). DNA-PK phosphorylates histone H2AX during apoptotic DNA fragmentation
in mammalian cells. DNA Repair 5, 575–590.
Murga, M., Bunting, S., Montaña, M. F., Soria, R., Mulero, F., Cañamero, M., et al. (2010). A
mouse model of ATR–Seckel shows embryonic replicative stress and accelerated
aging. Nat Genet 41, 891–898.
Murga, M., Campaner, S., Lopez-Contreras, A. J., Toledo, L. I., Soria, R., Montaña, M. F., et al.
(2011). Exploiting oncogene-induced replicative stress for the selective killing of
Myc-driven tumors. Nat Struct Mol Biol 18, 1331–1335.
Myers, K., Gagou, M. E., Zuazua-Villar, P., Rodriguez, R., &Meuth, M. (2009). ATR and Chk1
suppress a caspase-3-dependent apoptotic response following DNA replication stress.
PLoS Genet 5, e1000324.
Negrini, S., Gorgoulis, V. G., & Halazonetis, T. D. (2010). Genomic instability—An evolving
hallmark of cancer. Nat Rev Mol Cell Biol 11, 220–228.
Newton, R., Broughton, L. J., Lind, M. J., Morrison, P. J., Rogers, H. J., & Bradbrook, I. D.
(1981). Plasma and salivary pharmacokinetics of caffeine inman. Eur J Clin Pharmacol
21, 45–52.
Nghiem, P., Park, P. K., Kim Ys, Y., Desai, B. N., & Schreiber, S. L. (2002). ATR is not required
for p53 activation but synergizes with p53 in the replication checkpoint. J Biol Chem
277, 4428–4434.
Nishida, H., Tatewaki, N., Nakajima, Y., Magara, T., Ko, K. M., Hamamori, Y., et al. (2009).
Inhibition of ATR protein kinase activity by schisandrin B in DNA damage response.
Nucleic Acids Res 37, 5678–5689.
O'Driscoll, M., Ruiz-Perez, V. L., Woods, C. G., Jeggo, P. A., & Goodship, J. A. (2003). A splic-
ing mutation affecting expression of ataxia–telangiectasia and Rad3-related protein
(ATR) results in Seckel syndrome. Nat Genet 33, 497–501.
O'Neill, T., Dwyer, A. J., Ziv, Y., Chan, D. W., Lees-Miller, S. P., Abraham, R. H., et al. (2000).
Utilization of oriented peptide libraries to identify substrate motifs selected by ATM. J
Biol Chem 275, 22719–22727.
137A.M. Weber, A.J. Ryan / Pharmacology & Therapeutics 149 (2015) 124–138Oliver, T. G., Mercer, K. L., Sayles, L. C., Burke, J. R., Mendus, D., Lovejoy, K. S., et al. (2010).
Chronic cisplatin treatment promotes enhanced damage repair and tumor progression
in a mouse model of lung cancer. Genes Dev 24, 837–852.
Olivier, M., Hollstein, M., & Hainaut, P. (2010). TP53mutations in human cancers: Origins,
consequences, and clinical use. Cold Spring Harb Perspect Biol 2, a001008.
Ottini, L., Falchetti, M., Saieva, C., De Marco, M., Masala, G., Zanna, I., et al. (2004). MRE11
expression is impaired in gastric cancer with microsatellite instability. Carcinogenesis
25, 2337–2343.
Ozeri-Galai, E., Schwartz, M., Rahat, A., & Kerem, B. (2008). Interplay between
ATM and ATR in the regulation of common fragile site stability. Oncogene 27,
2109–2117.
Pal, T., Permuth-Wey, J., Betts, J. a, Krischer, J. P., Fiorica, J., Arango, H., et al. (2005). BRCA1
and BRCA2 mutations account for a large proportion of ovarian carcinoma cases.
Cancer 104, 2807–2816.
Paull, T. T., Rogakou, E. P., Yamazaki, V., Kirchgessner, C. U., Gellert, M., & Bonner, W. M.
(2000). A critical role for histone H2AX in recruitment of repair factors to nuclear
foci after DNA damage. Curr Biol 10, 886–895.
Peasland, A., Wang, L. -Z., Rowling, E., Kyle, S., Chen, T., Hopkins, A., et al. (2011).
Identiﬁcation and evaluation of a potent novel ATR inhibitor, NU6027, in breast and
ovarian cancer cell lines. Br J Cancer 105, 372–381.
Peng, C. -Y., Graves, P. R., Thoma, R. S., Wu, Z., Shaw, A. S., & Piwnica-Worms, H. (1997).
Mitotic and G2 checkpoint control: Regulation of 14-3-3 protein binding by
phosphorylation of Cdc25C on serine-216. Science 277, 1501–1505.
Petitjean, A., Mathe, E., Kato, S., Ishioka, C., Sean, V., Hainaut, P., et al. (2007). Impact of
mutant p53 functional properties on TP53 mutation patterns and tumor phenotype:
Lessons from recent developments in the IARC TP53 database. HumMutat 28, 622–629.
Pires, I. M., Olcina, M. M., Anbalagan, S., Pollard, J. R., Reaper, P. M., Charlton, P. A., et al.
(2012). Targeting radiation-resistant hypoxic tumour cells through ATR inhibition.
Br J Cancer 107, 291–299.
Powell, S. N., DeFrank, J. S., Connell, P., Eogan, M., Preffer, F., Dombkowski, D., et al.
(1995). Differential sensitivity of p53(−) and p53(+) cells to caffeine-induced
radiosensitization and override of G2 delay. Cancer Res 55, 1643–1648.
Prevo, R., Fokas, E., Reaper, P. M., Charlton, P. A., Pollard, J. R., McKenna, W. G., et al.
(2012). The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer
cells to radiation and chemotherapy. Cancer Biol Ther 13, 1072–1081.
Price, B. D., & Youmell, M. B. (1996). The phosphatidylinositol 3-kinase inhibitor
Wortmannin sensitizes murine ﬁbroblasts and human tumor cells to radiation and
blocks induction of p53 following DNA damage. Cancer Res 56, 246–250.
Rainey, M. D., Charlton, M. E., Stanton, R. V., & Kastan, M. B. (2008). Transient inhibition of
ATM kinase is sufﬁcient to enhance cellular sensitivity to ionizing radiation. Cancer
Res 68, 7466–7474.
Reaper, P. M., Grifﬁths, M. R., Long, J. M., Charrier, J. -D., Maccormick, S., Charlton, P. A.,
et al. (2011). Selective killing of ATM- or p53-deﬁcient cancer cells through inhibition
of ATR. Nat Chem Biol 7, 428–430.
Riesterer, O., Matsumoto, F., Wang, L., Pickett, J., Molkentine, D., Giri, U., et al. (2011). A
novel Chk inhibitor, XL-844, increases human cancer cell radiosensitivity through
promotion of mitotic catastrophe. Invest New Drugs 29, 514–522.
Roossink, F., Wieringa, H.W., Noordhuis, M. G., ten Hoor, K. A., Kok, M., Slagter-Menkema,
L., et al. (2012). The role of ATM and 53BP1 as predictive markers in cervical cancer.
Int J Cancer 131, 2056–2066.
Roy, K.,Wang, L., Makrigiorgos, G.M., & Price, B. D. (2006).Methylation of the ATMpromoter
in glioma cells alters ionizing radiation sensitivity. Biochem Biophys Res Commun 344,
821–826.
Ruzankina, Y., Pinzon-Guzman, C., Asare, A., Ong, T., Pontano, L., Cotsarelis, G., et al.
(2007). Deletion of the developmentally essential gene ATR in adult mice leads to
age-related phenotypes and stem cell loss. Cell Stem Cell 1, 113–126.
Ruzankina, Y., Schoppy, D. W., Asare, A., Clark, C. E., Vonderheide, R. H., & Brown, E. J. (2009).
Tissue regenerative delays and synthetic lethality in adult mice after combined deletion
of Atr and Trp53. Nat Genet 41, 1144–1149.
Sanchez, Y., Wong, C., Thoma, R. S., Richman, R., Wu, Z., Piwnica-Worms, H., et al. (1997).
Conservation of the Chk1 checkpoint pathway in mammals: Linkage of DNA damage
to Cdk regulation through Cdc25. Science 277, 1497–1501.
Sandoval, N., Platzer, M., Rosenthal, A., Dörk, T., Bendix, R., Skawran, B., et al. (1999).
Characterization of ATM gene mutations in 66 ataxia telangiectasia families. Hum Mol
Genet 8, 69–79.
Sangster-Guity, N., Conrad, B. H., Papadopoulos, N., & Bunz, F. (2011). ATR mediates
cisplatin resistance in a p53 genotype-speciﬁc manner. Oncogene 30, 2526–2533.
Sarkaria, J. N., Busby, E. C., Tibbetts, R. S., Roos, P., Taya, Y., Karnitz, L. M., et al. (1999).
Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine.
Cancer Res 59, 4375–4382.
Sarkaria, J. N., Tibbetts, R. S., Busby, E. C., Kennedy, A. P., Hill, D. E., & Abraham, R. T. (1998).
Inhibition of phosphoinositide 3-kinase related kinases by the radiosensitizing agent
Wortmannin. Cancer Res 58, 4375–4382.
Savitsky, K., Bar-Shira, A., Gilad, S., Rotman, G., Ziv, Y., Vanagaite, L., et al. (1995). A single
ataxia telangiectasia gene with a product similar to PI-3 kinase. Science 268, 1749–1753.
Schoppy, D. W., Ragland, R. L., Gilad, O., Shastri, N., Peters, A. A., Murga, M., et al. (2012).
Oncogenic stress sensitizes murine cancers to hypomorphic suppression of ATR. J Clin
Invest 122, 241–252.
Scully, R., & Xie, A. (2013). Double strand break repair functions of histone H2AX. Mutat
Res 750, 5–14.
Shiloh, Y. (2001). ATM and ATR: Networking cellular responses to DNA damage. Curr Opin
Genet Dev 11, 71–77.
Shiloh, Y. (2003). ATM and related protein kinases: Safeguarding genome integrity. Nat
Rev Cancer 3, 155–168.
Shiloh, Y., & Ziv, Y. (2013). The ATM protein kinase: Regulating the cellular response to
genotoxic stress, and more. Nat Rev Mol Cell Biol 14, 197–210.Siliciano, J. D., Canman, C. E., Taya, Y., Sakaguchi, K., Appella, E., & Kastan, M. B. (1997).
DNA damage induces phosphorylation of the amino terminus of p53. Genes Dev 11,
3471–3481.
Sørensen, C. S., Syljuåsen, R. G., Falck, J., Schroeder, T., Rönnstrand, L., Khanna, K. K., et al.
(2003). Chk1 regulates the S phase checkpoint by coupling the physiological turnover
and ionizing radiation-induced accelerated proteolysis of Cdc25A. Cancer Cell 3,
247–258.
Sprong, D., Janssen, H. L., Vens, C., & Begg, A. C. (2006). Resistance of hypoxic cells to ionizing
radiation is inﬂuenced by homologous recombination status. Int J Radiat Oncol Biol Phys
64, 562–572.
Stracker, T. H., & Petrini, J. H. J. (2011). The MRE11 complex: Starting from the ends. Nat
Rev Mol Cell Biol 12, 90–103.
Subramanian, L., & Nakamura, T. M. (2010). A kinase-independent role for the Rad3(ATR)-
Rad26(ATRIP) complex in recruitment of Tel1(ATM) to telomeres in ﬁssion yeast.
PLoS Genet 6, e1000839.
Sullivan, K. D., Gallant-Behm, C. L., Henry, R. E., Fraikin, J. -L., & Espinosa, J. M. (2012). The
p53 circuit board. Biochim Biophys Acta 1825, 229–244.
Sultana, R., Abdel-Fatah, T., Abbotts, R., Hawkes, C., Albarakati, N., Seedhouse, C., et al.
(2013). Targeting XRCC1 deﬁciency in breast cancer for personalized therapy.
Cancer Res 73, 1621–1634.
Sultana, R., Abdel-Fatah, T., Perry, C., Moseley, P., Albarakti, N., Mohan, V., et al. (2013).
Ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase inhibition is
synthetically lethal in XRCC1 deﬁcient ovarian cancer cells. PLoS One 8, e57098.
Sultana, R., McNeill, D. R., Abbotts, R., Mohammed, M. Z., Zdzienicka, M. Z., Qutob, H.,
et al. (2012). Synthetic lethal targeting of DNA double-strand break repair deﬁ-
cient cells by human apurinic/apyrimidinic endonuclease inhibitors. Int J Cancer
131, 2433–2444.
Sun, Y., Xu, Y., Roy, K., & Price, B. D. (2007). DNA damage-induced acetylation of lysine
3016 of ATM activates ATM kinase activity. Mol Cell Biol 27, 8502–8509.
Taylor, A.M. R., Harnden, D. G., Arlett, C. F., Harcourt, S. A., Lehmann, A. R., Stevens, S., et al.
(1975). Ataxia telangiectasia: A humanmutation with abnormal radiation sensitivity.
Nature 258, 427–429.
Thanasoula, M., Escandell, J. M., Suwaki, N., & Tarsounas, M. (2012). ATM/ATR checkpoint
activation downregulates CDC25C to preventmitotic entry with uncapped telomeres.
EMBO J 31, 3398–3410.
Tibbetts, R. S., Brumbaugh, K. M., Williams, J. M., Sarkaria, J. N., Cliby, W. A., Shieh, S. -Y., et al.
(1999). A role for ATR in the DNA damage-induced phosphorylation of p53. Genes Dev
13, 152–157.
Tibbetts, R. S., Cortez, D., Brumbaugh, K. M., Scully, R., Livingston, D., Elledge, S. J., et al.
(2000). Functional interactions between BRCA1 and the checkpoint kinase ATR during
genotoxic stress. Genes Dev 14, 2989–3002.
Toledo, L. I., Murga, M., Zur, R., Soria, R., Rodriguez, A., Martinez, S., et al. (2011). A cell-based
screen identiﬁes ATR inhibitors with synthetic lethal properties for cancer-associated
mutations. Nat Struct Mol Biol 18, 721–727.
Tribius, S., Pidel, A., & Casper, D. (2001). ATM protein expression correlates with
radioresistance in primary glioblastoma cells in culture. Int J Radiat Oncol Biol
Phys 50, 511–523.
Turner, N. C., Lord, C. J., Iorns, E., Brough, R., Swift, S., Elliott, R., et al. (2008). A synthetic lethal
siRNA screen identifying genes mediating sensitivity to a PARP inhibitor. EMBO J 27,
1368–1377.
Tutt, A., Robson, M., Garber, J. E., Domchek, S. M., Audeh, M. W., Weitzel, J. N., et al.
(2010). Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with
BRCA1 or BRCA2 mutations and advanced breast cancer: A proof-of-concept
trial. Lancet 376, 235–244.
Van Gent, D. C., Hoeijmakers, J. H. J., & Kanaar, R. (2001). Chromosomal stability and the DNA
double-strand break connection. Nat Rev Genet 2, 196–206.
Vo, Q. N., Kim, W. -J., Cvitanovic, L., Boudreau, D. A., Ginzinger, D. G., & Brown, K. D.
(2004). The ATM gene is a target for epigenetic silencing in locally advanced breast
cancer. Oncogene 23, 9432–9437.
Ward, I. M., & Chen, J. (2001). Histone H2AX is phosphorylated in an ATR-dependent
manner in response to replicational stress. J Biol Chem 276, 47759–47762.
Ward, T. H., Cummings, J., Dean, E., Greystoke, A., Hou, J. M., Backen, A., et al. (2008). Bio-
markers of apoptosis. Br J Cancer 99, 841–846.
Weber, A. M., Bokobza, S. M., Devery, A. M., & Ryan, A. J. (2013). Combined ATM and ATR
kinase inhibition selectively kills p53-mutated non-small cell lung cancer (NSCLC)
cells. (abstract) Proceedings of the AACR-NCI-EORTC International Conference: Molecu-
lar Targets and Cancer Therapeutics; 2013 Oct 19–23. Mol Cancer Ther 2(11 Suppl.). Bos-
ton, MA; Philadelphia (PA): AACR. http://dx.doi.org/10.1158/1535-7163.TARG-13-
B91 (Abstract nr B91).
Weber, A. M., Devery, A. M., Bokobza, S. M., & Ryan, A. J. (2014). 927: Immunohistochem-
ical analysis reveals frequent tumoural loss of ATM protein expression in lung cancer
[abstract]. Eur J Cancer 50, S227.
Weston, V. J., Oldreive, C. E., Skowronska, A., Oscier, D. G., Pratt, G., Dyer, M. J. S., et al.
(2010). The PARP inhibitor olaparib induces signiﬁcant killing of ATM-deﬁcient lym-
phoid tumor cells in vitro and in vivo. Blood 116, 4578–4587.
White, J. S., Choi, S., & Bakkenist, C. J. (2010). Transient ATM kinase inhibition disrupts
DNA damage-induced sister chromatid exchange. Sci Signal 3, ra44.
Williamson, C. T., Kubota, E., Hamill, J. D., Klimowicz, A., Ye, R., Muzik, H., et al. (2012).
Enhanced cytotoxicity of PARP inhibition in mantle cell lymphoma harbouring
mutations in both ATM and p53. EMBO Mol Med 4, 515–527.
Williamson, C. T., Muzik, H., Turhan, A. G., Zamò, A., O'Connor, M. J., Bebb, D. G., et al.
(2010). ATM deﬁciency sensitizes mantle cell lymphoma cells to poly(ADP-ribose)
polymerase-1 inhibitors. Mol Cancer Ther 9, 347–357.
Wold, M. S. (1997). Replication protein A: A heterotrimeric, single-stranded DNA-
binding protein required for eukaryotic DNA metabolism. Annu Rev Biochem 66,
61–92.
138 A.M. Weber, A.J. Ryan / Pharmacology & Therapeutics 149 (2015) 124–138Woods, D., & Turchi, J. J. (2013). Chemotherapy induced DNA damage response:
Convergence of drugs and pathways. Cancer Biol Ther 14, 379–389.
Wouters, B. G., & Brown, J. M. (1997). Cells at intermediate oxygen levels can be more
important than the “hypoxic fraction” in determining tumor response to fractionated
radiotherapy. Radiat Res 147, 541–550.
Xiao, Z., Chen, Z., Gunasekera, A. H., Sowin, T. J., Rosenberg, S. H., Fesik, S., et al. (2003). Chk1
mediates S and G2 arrests through Cdc25A degradation in response to DNA-damaging
agents. J Biol Chem 278, 21767–21773.
Yamamoto, K., Wang, Y., Jiang, W., Liu, X., Dubois, R. L., Lin, C. -S., et al. (2012). Kinase-dead
ATM protein causes genomic instability and early embryonic lethality in mice. J Cell Biol
198, 305–313.
Yao, S. -L., Akhtar, A. J., McKenna KA, C. B. G., David, S., Mack, M., Rajani, R., et al. (1996).
Selective radiosensitization of p53-deﬁcient cells by caffeine-mediated activation of
p34cdc2 kinase. Nat Med 2, 1140–1143.
Yap, T. A., Sandhu, S. K., Carden, C. P., & de Bono, J. S. (2011). Poly(ADP-ribose) polymerase
(PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic. CA Cancer J Clin 61,
31–49.Yap, T. A., Sandhu, S. K., Workman, P., & de Bono, J. S. (2010). Envisioning the future of
early anticancer drug development. Nat Rev Cancer 10, 514–523.
You, Z., Chahwan, C., Bailis, J., Hunter, T., & Russell, P. (2005). ATM activation and its
recruitment to damaged DNA require binding to the C terminus of Nbs1. Mol Cell Biol
25, 5363–5379.
Zhao, Y., Thomas, H. D., Batey, M. A., Cowell, I. G., Richardson, C. J., Grifﬁn, R. J., et al.
(2006). Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor
NU7441. Cancer Res 66, 5354–5362.
Zhao, H., Watkins, J. L., & Piwnica-Worms, H. (2002). Disruption of the checkpoint kinase
1/cell division cycle 25A pathway abrogates ionizing radiation-induced S and G2
checkpoints. Proc Natl Acad Sci U S A 99, 14795–14800.
Zou, L., & Elledge, S. J. (2003). Sensing DNA damage through ATRIP recognition of
RPA–ssDNA complexes. Science 300, 1542–1548.
